Skip to main content
Independent report

Statement on the potential health risks of Echinacea in the maternal diet

Published 9 November 2026

Introduction

1. The Scientific Advisory Committee on Nutrition (SACN) last considered the maternal diet and nutrition in relation to offspring health in its reports on ‘The influence of maternal, foetal and child nutrition on the development of chronic disease in later life’ (SACN, 2011) and on ‘Feeding in the first year of life’ (SACN, 2018). In the latter report, the impact of breastfeeding on maternal health was also considered. In 2019, SACN agreed to conduct a risk assessment on nutrition and maternal health, focusing on maternal outcomes during pregnancy, childbirth and up to 24 months after delivery. Further information on the scope of the maternal health projects can be found in the Scope of the Nutrition and Maternal health project Annex.

2. SACN agreed that, where appropriate, other expert committees would be consulted and asked to complete relevant risk assessments. A provisional list of chemicals was proposed by SACN Members. However, this was subject to change following discussion by the COT. A scoping paper was presented to the Committee (TOX/2020/45COT Contribution to SACN review of nutrition and maternal health: proposed scope of work and timetable) to define the scope of the work from a toxicological safety perspective and request their input on the selection of candidate chemicals or chemical classes that could be added or removed.

3. As part of this work, the Committee decided it would be useful to consider the use of dietary supplements during pregnancy. A scoping paper (TOX/2020/51 Scoping paper on herbal supplements used in pregnancy) was presented, reviewing the dietary supplements commonly used during pregnancy. These supplements are not officially recommended by relevant health and regulatory authorities but are promoted by anecdotal evidence and unofficial sources as having various purported benefits.

4. The review presented in the scoping paper was confined to herbal dietary supplements which would be regulated under food law, as opposed to traditional herbal medicines, which are overseen by the Medicines and Healthcare Products Regulatory Agency (MHRA). Following this review, the COT suggested that Echinacea required further investigation, noting that both human and animal in vitro and in vivo data were available. The main areas of concern included general toxicity to the mother, effects on the development of the foetus or embryo and possible interactions with prescribed drugs.

5. Based on the COT’s recommendations, a more extensive literature search was undertaken to evaluate the safety of Echinacea use during pregnancy, and the results are presented below (for full details of the search method, see Appendix A).

Background

Uses

6. Echinacea is a genus of herbaceous flowering plants, comprised of ten species and originally native to North America (Ahmadi et al., 2024). Three Echinacea species (Echinacea purpurea, Echinacea pallida, and Echinacea angustifolia) are used medicinally for the prevention and treatment of the common cold, influenza, and upper respiratory tract infections (Ardjomand-Woelkart and Bauer, 2015). E. purpurea is the most widely used and extensively studied of the three. Prior to 1968, Echinacea angustifolia and Echinacea pallida were considered to be different varieties of the same species until a revision of the genus described them as two separate species (WHO, 1999).

7. Echinacea herbal products are often sold as dietary supplements to enhance immune function and reduce the symptoms and duration of common cold and upper respiratory tract infections. These are popular products in North America and Europe, generating more than 300 million USD annually in the U.S. alone (Ahmadi et al., 2024).

8. Echinacea extracts are used to treat a broad range of ailments including respiratory infections (colds and flu, bronchitis, strep throat, toothache), urinary tract infections, skin disorders (Staphylococcus infections, cold sores, ulcers, wounds, burns, insect bites, eczema, allergies) and rheumatoid arthritis (Hudson, 2012). Between 0.5% (Heitmann et al., 2016) and 9.2% (Cuzzolin et al., 2010) of pregnant women report using Echinacea during pregnancy for the treatment of colds and flu, to stimulate the immune system and to prevent the common cold (Cuzzolin et al., 2010; Holst et al., 2011).

Constituents and preparations

9. The whole plant, fresh or dried aerial parts and fresh pressed juice from the flowering tops of E. purpurea and the dried roots of E. purpurea, E. pallida and E. angustifolia are used medicinally. The final products can contain powdered plant parts, dry and liquid extracts, pressed and dried pressed juice (Barnes et al., 2010). Various methods of extraction are used to prepare Echinacea products.

10. The composition of bioactive compounds varies across the three medicinally used species and their respective plant parts. It is generally considered that there is no single chemical or a clearly defined group of chemicals responsible for the activity of Echinacea. The combined effects of several groups of bioactive compounds, including alkylamides, caffeic acid derivatives, echinacoside, cichoric acid, cynarin, flavonoids, polysaccharides and alkenes, all contribute to the biological activity of Echinacea (Barnes et al., 2010). There is also no consensus on which of the chemical constituent(s) should serve as a standardisation marker for Echinacea preparations.

11. Where information is available regarding the bioactive constituents of the specific Echinacea preparation used in the studies discussed in this statement, this has been reported for each study. If these details were not provided in the original study, the presence, identity, or concentration of bioactive components cannot be inferred or assumed.

Existing authorisations for Echinacea products in the UK

12. In the UK some Echinacea products are regulated by the MHRA under the Traditional Herbal Registration (THR) scheme (see Appendix B, Table 13). These products have been approved for the relief of common cold symptoms and influenza-type infections, symptomatic relief of minor skin conditions such as spots, pimples, and blemishes and relief of minor urinary complaints associated with cystitis in women. Approval is based on traditional use only, in adults and children over 12 years and for a maximum duration of 10 days. None of these products are recommended for pregnant or lactating women. Although Echinacea dietary supplements are the focus of this paper, products holding a THR are a source of information regarding doses and preparations of Echinacea. For further information on doses and preparations of THR Echinacea products and European Medicines Agency (EMA) monographs, see Appendix B, Table 14. It should be noted, however, that food supplements may differ significantly from EMA- or MHRA-approved herbal medicinal preparations in terms of preparation, composition, quality, and manufacturing standards. It may not, therefore, be appropriate to directly read across findings from studies or monographs on licensed products to food supplements.

13. A THR can only be granted by the MHRA following a formal application that meets all the required standards for quality, safety, evidence of traditional use, and other criteria as set out in the Human Medicines Regulations 2012 (HMR, 2012). The evidence of traditional use relates to the product having been in traditional medicinal use for a continuous period of at least 30 years, of which at least 15 years must be within the European Union (Part 7 HMR, 2012). The safety requirements are a bibliographic review of safety data together with an expert report on safety (Schedule 12, HMR, 2012).

European Medicines Agency assessment reports and conclusions

14. Specific preparations containing Echinacea purpurea (L.) Moench, E. angustifolia DC (radix), and E. pallida (Nutt.) Nutt. (radix), that are authorised or registered as herbal medicinal products in EU/EEA Member States, are covered by EMA herbal monographs. The EMA framework specifies that the main regulatory pathways for bringing a herbal medicinal product to market in EU Member States are traditional use registration or well-established use marketing authorisation. For traditional use, herbal medicinal products can be registered under Article 16a of Directive 2001/83/EC if they have been in medicinal use for at least 30 years, including 15 years within the EU. Evidence of efficacy is based on bibliographic and historical data, demonstrating plausible efficacy and safety, without requiring clinical trials. These products are intended for minor conditions suitable for self-medication and must not be administered by injection. For well-established medicinal use, herbal medicinal products qualify under Article 10a of Directive 2001/83/EC when their active substances have been in well-established medicinal use within the EU for at least 10 years, supported by scientific literature showing recognised efficacy and acceptable safety.

15. The EMA has published detailed assessment reports on three medicinally used species: E. purpurea (L.) Moench. (EMA, 2014), E. angustifolia DC, radix (EMA, 2012) and E. pallida (Nutt.) Nutt., radix (EMA, 2018). The EMA assessment reports include specifications for the herbal substances (e.g. active constituents) and details on the herbal preparations themselves. In contrast, such specifications are not available for Echinacea-based foods and food supplements, making direct extrapolation from EMA conclusions challenging.

16. According to the EMA assessment report on E. purpurea, the European Pharmacopoeia defines the herbal substance as the dried, whole or cut flowering aerial parts of E. purpurea with a minimum of 0.1% combined caftaric and cichoric acids content. It is also stated that US Pharmacopeia requires at least 1.0% cichoric acid and 0.01% dodecatetraenoic acid isobutylamides on a dry basis, detailed in the E. purpurea aerial parts pharmacopoeia monograph. Furthermore, the EMA report details that major constituents of E. purpurea include caffeic acid derivatives (cichoric acid 1–5%, caftaric acid, minor feruloyl-tartaric acid), alkylamides (notably dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide), polysaccharides such as PS I (35 kDa) and PS II (450 kDa), and volatile oils (0.08 – 0.32%) including borneol, bornyl acetate, germacrene D, and caryophyllene (EMA, 2014). The herbal preparation for well-established use consists of expressed juice with drug extract ratio (DER) of 1.5 - 2.1:1 or the dried juice corresponding to expressed juice (EMA monograph, 2014).

17. The EMA assessment report on E. angustifolia specifies that, according to the European Pharmacopoeia, Echinacea angustifolia radix consists of the whole or cut, dried underground parts of E. angustifolia DC and must contain not less than 0.5 % echinacoside. The EMA report details that major constituents of E. angustifolia root include caffeic acid derivatives (1.0 – 1.4%), cynarin (0.12 – 0.14%), chlorogenic acid and cichoric acid. Alkylamides are present at about 0.5%, mainly as isobutylamides and 2-methylbutylamides of straight-chain fatty-acids with olefinic and/or acetylenic bonds e.g. isomeric dodeca-2E,4E,8Z,10E/Z-tetraenoic isobutylamide. The root also contains polysaccharides and glycoproteins, including two polysaccharides (128 kDa and 4.5 kDa) and three glycoproteins (17–30 kDa), with the dominant sugars being arabinose (64–84%), galactose (2–5%), and glucosamine (6%). Volatile oils occur in small amounts (~0.1%) and include dodeca-2,4-diene-1-yl isovalerate and pentadeca-1,8Z-diene. Other constituents include phytomelanin and trace levels of saturated pyrrolizidine-type alkaloids (tussilagine and isotussilagine, approximately 0.006%) (EMA, 2012). The herbal preparation for traditional use consists of comminuted or powdered herbal substance, tincture (ratio of herbal substance to extraction solvent 1:5) or liquid extract (DER 1:1). Both tincture and liquid extract are obtained with 45% v/v ethanol extraction solvent (EMA monograph, 2012).

18. The EMA assessment report on E. pallida states that, according to the European Pharmacopoeia, Echinaceae pallidae radix consists of the whole or cut, dried underground parts of E. pallida (Nutt.) Nutt and must contain not less than 0.2% echinacoside in the dried drug. Its major constituents are phenylpropanoids, particularly caffeic acid derivatives such as echinacoside (0.5–1.0%), chlorogenic acid, isochlorogenic acid, cynarin, and minor amounts of caftaric and cichoric acids. Unlike other species, alkylamides are essentially absent (approximately 0.001%). The root also contains phytomelanin, polysaccharides and glycoproteins, volatile oils (0.2–2.0%) including polyenes, polyacetylenes, ketoalkenes, and ketoalkenynes (EMA, 2018). The herbal preparation for traditional use consists of dry extract (DER 4-8:1) or tincture (ratio of herbal substance to extraction solvent 1:5), both obtained with 50% v/v ethanol extraction solvent (EMA monograph, 2018).

19. Studies on reproductive toxicity, genotoxicity and carcinogenicity had not been performed for preparations of E. pallida (EMA, 2018) or E. angustifolia (EMA, 2012) at the time the EMA reports were written. In the absence of these data, the use of these species in pregnancy and lactation was not recommended by EMA. Due to the lack of genotoxicity data, the EMA did not recommend the addition of E. pallida (EMA, 2018) and E. angustifolia (EMA, 2012) to the Community list of herbal substances, herbal preparations and combinations thereof for traditional medicinal products. There were also insufficient clinical data to support the criteria for well-established medicinal use of E. angustifolia and E. pallida roots, in accordance with Directive 2001/83/EC. The traditional use of E. angustifolia and E. pallida root extracts for the relief of common cold symptoms was deemed as acceptably safe by EMA due to a longstanding history of use without reports of serious adverse effects.

20. E. purpurea is on the Community list of herbal substances, herbal preparations and combinations thereof for traditional medicinal products based on traditional topical use for the treatment of small superficial wounds (HMPC, 2007). The benefit-risk assessment conducted by EMA concluded that there was sufficient clinical evidence to support the well-established medicinal use, in accordance with Directive 2001/83/EC, of expressed juice preparations from E. purpurea fresh herb for the short-term prevention (maximum 10 days) and treatment of common cold in adults and children over the age of 12 (EMA, 2014).

21. No genotoxic or mutagenic effects have been observed in bacterial reverse mutation tests, human lymphocyte assays or micronucleus assays with lyophilised E. purpurea (EMA, 2014). The EMA identified limited epidemiological data suggesting no adverse effects associated with oral E. purpurea use and pregnancy outcomes (EMA, 2014). However, the EMA did not recommend its use (both topical and oral) during pregnancy and lactation due to the lack of guideline-compliant preclinical data on reproductive and developmental toxicity.

Health-based guidance values (HBGVs)

22. There are currently no health-based guidance values (HBGVs) with respect to Echinacea or its constituents.

Guideline compliance of studies discussed

23. Where the studies referenced in this statement were conducted in accordance with Good Laboratory Practice (GLP) regulations or were Organisation for Economic Co-operation and Development (OECD) Test Guideline (TG)-compliant, this is stated in the section in which the study is discussed. In the absence of such a statement, compliance with GLP and/or OECD TG requirements should not be assumed.

Toxicokinetics

Animal studies

24. Jeong et al. (2024) conducted a pharmacokinetic analysis of pure chicoric acid and a standardised E. purpurea extract containing at least 2% chicoric acid to determine whether the crude extract formulation affected systemic exposure to the active component. Male Sprague Dawley (SD) rats received either highly purified chicoric acid administered intravenously or orally at 10 mg/kg, or the standardised E. purpurea extract administered orally at doses equivalent to 20 or 100 mg/kg chicoric acid (i.e. 1 and 5 g/kg extract), in five animals per dose group. Plasma samples were collected before dosing and 0.5, 1, 3, 5, 7, 9, 12, 14, 24 and 30 hours after dosing. The authors reported that pharmacokinetic parameters such as clearance, apparent volume of distribution, and elimination half‑life were comparable between purified chicoric acid and the Echinacea extract-derived chicoric acid. The study authors concluded that the presence of the crude extract matrix did not meaningfully alter the pharmacokinetic profile of chicoric acid.

Human studies

25. The EMA assessment reports on E. purpurea (EMA, 2014) and E. angustifolia (EMA, 2012) note that available pharmacokinetic data are limited and primarily focus on alkylamides and, to a lesser extent, caffeic acid conjugates. According to the human pharmacokinetic studies reviewed in the EMA reports, the alkylamides from E. purpurea and E. angustifolia show good oral bioavailability with rapid absorption and measurable plasma concentration within 20 - 60 minutes post-ingestion. The reported peak plasma concentration Cmax values for alkylamides varied between studies from 0.04 ng/mL for E. purpurea alkylamides (Goey et al., 2012) to over 300 ng/mL for E. purpurea/E. angustifolia alkylamides (Matthias et al., 2005). The EMA highlighted that these discrepancies are likely due to the differing alkylamide profiles of Echinacea species and lack of comparability in extract concentrations, analytical methods and study design. Caffeic acid derivatives were not detected in plasma after oral administration and their oral bioavailability was questioned by the EMA assessors (EMA, 2014). The key pharmacokinetic studies from the EMA assessment reports are briefly outlined below.

E. purpurea

26. In a small clinical study by Goey et al. (2012), three cancer patients (age and sex not specified) received 20 drops of a commercial E. purpurea extract (65% V/V ethanol extract of freshly harvested E. purpurea herb (drug extract ratio (DER) 1:12)) and roots (DER 1:11) three times daily for 14 days. Blood samples for pharmacokinetic analysis of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides (DTAI) were drawn at 0, 30, 60 and 120 minutes after the morning dose on day 15. For all three patients the plasma concentration–time curves showed a similar time course with a maximum plasma concentration of DTAI (0.04–0.18 ng/mL) achieved at 30 minutes after ingestion. The authors stated that the findings indicated low systemic exposure to alkylamides after repeated oral dosing. However, the COT noted that the study is highly limited due to the very small sample size and the fact that it was conducted in cancer patients who may have been receiving other anticancer drugs, reducing the relevance of the findings for healthy individuals.

E. angustifolia

27. In a randomised, open-label, crossover study, eleven healthy subjects (five men and six women aged 25–36 years) received a single oral 2.5 mL dose of a 60% ethanolic extract from E. angustifolia roots (Woelkart et al., 2005). The maximum plasma concentration of DTAI, the main alkylamides in E. angustifolia roots, of 10.88 ng/mL was reached at 30 minutes post dose. The authors noted that highly lipophilic alkylamides with no double and triple bond at the end of the fatty acid chain could not be detected in the blood.

E. angustifolia/E. purpurea

28. Eleven healthy volunteers, males and females aged 18-26 years, received Echinacea orally (4 tablets, each containing extract equivalent to 675 mg of E. purpurea root plus 600 mg of E. angustifolia root prepared from the dried ethanolic extracts of the two Echinacea species, equivalent to a total dose of 2,700 mg E. purpurea root and 2,400 mg E. augustifolia root) immediately after a high fat breakfast (n=9) or fasted state (n=2) (Matthias et al. 2005). Blood samples were taken prior to tablet ingestion and 0.33, 0.66, 1.0, 1.33, 1.66, 2.0, 2.5, 3.0, 3.5, 4, 6, 8, 10, and 12 hours post dose. Caffeic acid conjugates could not be identified in any plasma sample at any time after tablet ingestion. Alkylamides were rapidly absorbed; they were measurable in plasma 20 minutes after tablet ingestion and remained detectable for up to 12 hours. Maximal concentrations for the sum of alkylamides in human plasma were reached within 2.3 hours post ingestion and averaged 336 +/- 131 ng/mL plasma. The authors reported that the presence of food did not appear to influence the rate of alkylamide uptake; plasma concentrations in the fasted state were within the range observed in subjects who consumed Echinacea after a standard high fat breakfast. They concluded that alkylamides from Echinacea preparations were orally bioavailable and their pharmacokinetics supported the three times daily regimen already recommended for Echinacea.

Effects on cytochrome P450 and P-glycoprotein

29. Freeman and Spelman (2008) conducted a literature review and found no verifiable reports of drug–herb interactions involving Echinacea products. They noted that herbal remedies derived from E. purpurea appear to have a low potential for cytochrome P450 (CYP)-mediated interactions. The authors further estimated that, given the risk of adverse events (approximately 1 in 100,000), the annual consumption of Echinacea doses (around 10 million), and the fact that most use is short-term, products containing E. purpurea (roots and/or aerial parts) do not pose a significant risk to consumers. Nevertheless, they concluded that although current evidence does not support the need for specific precautions when Echinacea is co-administered with prescription medications, a prudent clinical approach would be to monitor patients taking Echinacea concurrently with substrates of CYP3A4 or CYP1A2.

30. The in vitro studies identified as part of the literature search performed by the Secretariat suggest that Echinacea has the potential to inhibit CYP3A4 (Yale and Glurich, 2005; Modarai et al. 2010; Hellum et al. 2007; Husain et al., 2023), CYP1A2 (Yale and Glurich, 2005; Hellum et al. 2007), CYP2E1 (Raner et al. (2007), CYP2C9 (Yale and Glurich, 2005), CYP2C19 (Modarai et al., 2010) and P-glycoprotein (Husain et al., 2023; Hansen and Nilsen, 2009). Some in vitro studies reported a positive association between the total alkylamide content of the Echinacea preparation and its ability to inhibit CYP3A4 (Modarai et al. 2010) and CYP1A2 (Raner et al. 2007).

31. A clinical study on human volunteers (six men and six women) by Gorski (2004) found that E. purpurea root extract (Nature’s Bounty) taken orally at 400 mg four times a day (1,600 mg/day) for 8 days was capable of causing significant changes in drug disposition by inhibiting CYP1A2 and intestinal CYP3A4 activity and by inducing hepatic CYP3A4 activity. This preparation contained greater than 1% phenols (caftaric acid, chlorogenic acid, echinacoside and chicoric acid). Gorski (2004) concluded that the modest change in the clearance of compounds metabolised by CYP1A2 is considered clinically significant as this can lead to increased toxicity of narrow therapeutic window drugs such as theophylline, which is a substrate for CYP1A2. The authors also speculated that other drugs metabolised by CYP1A2 such as cyclobenzaprine, tacrine, and clozapine can be affected by Echinacea co-administration.

32. Another human study with twelve healthy volunteers (six men and six women) investigated the effects of E. purpurea (800 mg twice daily, providing a daily dose of 43.8 mg cichoric acid) for 28 days on CYP1A2, CYP2D6, CYP2E1 and CYP3A4 phenotypes (Gurley et al., 2004). The administration of E. purpurea did not significantly change the activities of CYP3A4, CYP2E1, and CYP2D6 as estimated by comparing the phenotype ratios before and after treatment. Co-administration of E. purpurea caused an approximately 13% decrease in the ratio of paraxanthine/caffeine, suggesting a possible inhibitory effect on CYP1A2. However, the difference was not statistically significant, and the authors did not think it was clinically relevant (Gurley et al., 2004).

Drug-herb interactions

33. Khaksary Mahabady et al. (2006) assessed whether E. purpurea extract or levamisole could reduce phenytoin-induced cleft palate in NMRI mice. Thirty-two pregnant NMRI mice were equally divided into four groups: saline control (10 mL/kg), phenytoin only (65 mg/kg), phenytoin (65 mg/kg) + levamisole (10 mg/kg), and phenytoin (65 mg/kg) + E. purpurea extract (360 mg/kg). All drugs were administered intraperitoneally from the first day of gestation, which was assumed to be upon the discovery of a vaginal plug following mating. The study reported that phenytoin alone caused cleft palate in 16% of foetuses, while levamisole and E. purpurea reduced this to 5.3% and 3.2%, respectively. Foetal weight and length were significantly reduced in the phenytoin only group but remained normal in the other treatment groups. The authors concluded that the observed protective activity of levamisole and Echinacea against phenytoin-induced cleft palate was due to the immunomodulating and anti-inflammatory effects of these agents.

Reproductive and developmental studies on Echinacea

Animal studies

34. There are no OECD guideline-compliant in vivo studies on the reproductive and developmental toxicity of medicinally used Echinacea species.

35. Several studies which did not claim guideline compliance have investigated the effects of E. purpurea during pregnancy in mice (Barcz, E. et al., 2007; Chow et al., 2006) and pigs (Maass et al., 2005) and the reproductive and immune parameters of E. pallida have been investigated in pregnant rabbits (Dabbou et al., 2016) and their offspring (Kovitvadhi et al., 2016). No studies were found on the reproductive effects of E. angustifolia. The animal studies describing the reproductive and developmental effects of Echinacea are outlined below.

E. purpurea

36. Chow et al. (2006) investigated the potential association between E. purpurea consumption and spontaneous abortion in pregnant DBA/2 mice. Pregnant DBA/2 mice were randomised on the day a vaginal plug was detected to receive either E. purpurea–supplemented chow (n = 6) or standard Purina mouse chow (n = 7). An additional group of non pregnant mice (n = 7) received standard chow. The Echinacea supplemented diet was prepared by homogenising a commercially produced E. purpurea extract into finely ground standard chow, ensuring that individual mice consumed 0.45 mg/kg bw/day of the extract until they were euthanised (gestation days 10-14).

37. The study reported that Echinacea-fed mice showed effects in the spleen, with reduced numbers of lymphocytes and nucleated erythroid cells (to levels comparable to those in non-pregnant mice), whereas bone marrow parameters were not influenced by Echinacea supplementation. There was no significant difference in foetal count in early pregnancy (days 10 – 11), but by days 12 – 14 only 50% of foetuses survived in the Echinacea-fed group compared to controls (4 foetuses per pregnancy in controls vs 2 foetuses per pregnancy in Echinacea treatment group). The authors concluded that Echinacea may increase miscarriage risk in early pregnancy and advised against its use during this period.

38. Barcz et al. (2007) aimed to investigate whether administration of pharmaceuticals containing desiccated alcoholic extracts of E. purpurea to pregnant Balb/c mice influences foetal number, angiogenic activity, tissue vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) levels. Eight female mice received 0.6 mg E. purpurea extract daily, dissolved in water, and administered orally via an Eppendorf pipette from the 1st day of fertilization until the 18th day of pregnancy. Four mice were given vehicle control. Within the experimental group, different E. purpurea formulations were used: three mice were given Esberitox, two received Immunal, and three received Echinapur. The authors did not report the compositions of these formulations. Based on an online search conducted by the Secretariat, Esberitox contains 3.2 mg dry extract (4–9:1) from a mixture of wild indigo rootstock, purple coneflower root, pale coneflower root, and arbor vitae tips and leaves (4.92:1; 85:1; and 85:1) per tablet; Immunal contains 1,140 mg of dry extract from fresh E. purpurea herb (1:12) and 60 mg of dry extract from fresh E. purpurea root (1:11) per tablet; and Echinapur contains 100 mg of viscous extract from E. purpurea herb (DER 30–40:1; extractant: ethanol 23–30% v/v).

39. On day 18, females were sacrificed and the foetuses were extracted, counted, weighed and homogenised for angiogenic assessment. Angiogenic activity was assessed using the embryo-induced angiogenesis (EIA) test. Briefly, 0.05 mL of foetal tissue homogenate was injected intradermally into the shaved flanks of anaesthetised syngeneic Balb/c mice (two to three recipient mice per litter). After 72 hours, the mice were sacrificed and newly formed blood vessels growing towards the injection site were counted microscopically. VEGF and bFGF concentrations in the homogenates were quantified using an enzyme-linked immunosorbent assay (ELISA).

40. Barcz et al. (2007) reported that Echinapur and Esberitox groups showed a non-significant reduction in mean litter size compared to controls. However, all Echinacea treatments significantly reduced foetal VEGF and bFGF levels compared to controls (p < 0.0001 obtained by Analysis of variance (ANOVA) with post-hoc Tukey test). The angiogenic activity of the tissue homogenates, expressed as mean number of blood vessels, increased significantly in the Esberitox group, decreased in the Immunal group, and remained unchanged with Echinapur. The authors concluded that E. purpurea preparations may influence foetal angiogenesis and should not be recommended in pregnancy without further studies being carried out.

41. Maass et al. (2005) evaluated the effects of dietary E. purpurea in pregnant sows from day 85 of gestation to day 28 of lactation. Thirty-six sows were divided into three equal groups sizes receiving 0%, 1.2% (pregnancy)/0.5% (lactation), or 3.6% (pregnancy) /1.5% (lactation) Echinacea supplement, where the percentages represent the proportion of Echinacea supplement included in the feed. The feed amount was restricted to 2.6 kg/sow/day during pregnancy and offered ad libitum (max. 6 kg/sow/day) during lactation, resulting in similar daily Echinacea intakes across both periods. The Echinacea supplement consisted of ground cobs made from the dried and pressed aerial parts of E. purpurea. Two batches were used, with constituent levels varying due to processing and storage: in the first batch, cichoric acid declined from 420 to 290 mg/100 g plant dry matter and alkamides from 67.5 to 10.7 mg/100 g dry matter over the study period, while the second batch contained 170 mg/100 g dry matter cichoric acid and 44.1 mg/100 g dry matter alkamides. For this study, the litter size was set at 8–12 piglets.

42. Maass et al. (2005) reported that Echinacea supplementation had no measurable effect on release of liver enzymes (alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma‑glutamyl transferase) into the maternal circulation or on haematological parameters. No statistical differences in numbers of leukocytes, erythrocytes, lymphocytes, granulocytes, neutrophils, eosinophils, basophils, or monocytes were observed between supplemented and control sows. Colostrum crude protein content was 5% lower in the higher‑dose Echinacea group compared with controls, although this difference was not statistically significant (p < 0.11 obtained by ANOVA with post-hoc Student–Newman–Keuls test). Maternal daily weight gain during gestation was 18% higher in the control group than supplemented groups, but weight loss during lactation did not differ between groups. Regarding offspring outcomes, piglet birth weight in the control group was 4% lower than in the Echinacea‑supplemented groups, although this difference was not significant. No significant differences were observed in the growth performance of suckling piglets.

E. pallida

43. Two linked studies investigated the effects of E. pallida supplementation in rabbits. In the first study (Dabbou et al., 2016), 14-week old does (50 per group) were fed either a standard diet or one supplemented with 3 g per kg of diet E. pallida from insemination to weaning. The HPLC analysis of the Echinacea preparation identified caftaric acid, chicoric acid, chlorogenic acid and echinacoside, with echinacoside (0.37%) found to be the main caffeic acid derivative. The study reported no differences between Echinacea supplemented and control does in maternal body weight at kindling, kindling rate, blood morphology parameters, red and white blood cell indices, platelet measures, and serum biochemical markers (total protein, glutamic oxaloacetic transaminase, blood urea nitrogen, albumin, urea, and cholesterol). Basophil counts were slightly reduced in the supplemented group, but this difference was not statistically significant. Regarding offspring outcomes, litter size at birth and at days 21 and 35, as well as kit mortality, did not differ between groups. The authors concluded that supplementation with E. pallida did not produce any significant effects on reproductive, haematological, or immune parameters in does.

44. The follow-up study (Kovitvadhi et al., 2016) assessed the offspring of these does. Weaned kits were allocated into four groups (20 per group) based on maternal diet and post-weaning diet: (1) offspring from control does, fed the control diet, (2) offspring from control does, fed the Echinacea supplemented diet, (3) offspring from Echinacea-supplemented does, fed the control diet, and (4) offspring from Echinacea-supplemented does, fed the supplemented diet. The diets consisted of a commercial basal feed with or without E. pallida supplementation (3 g per kg of diet). Parameters measured included growth, microbiome composition, blood biochemistry, phagocytic activity, and humoral immune response. The study reported no significant differences in growth performance, blood parameters, bacterial community or humoral immune response in the offspring.

Human studies

45. Human data on Echinacea use during pregnancy are limited and primarily based on observational studies and surveys. Two prospective studies (Gallo et al., 2000; Heitmann et al., 2016) reported no increase in adverse pregnancy outcomes and no effects on gestational age, birth weight or major malformations with Echinacea use during pregnancy; however, information on the Echinacea species consumed, preparation, dose and duration was often incomplete. Survey data (Cuzzolin et al., 2010; Nordeng et al., 2011) also found no association between Echinacea use during pregnancy and adverse maternal or infant outcomes. Overall, the available human studies do not indicate adverse effects associated with use of Echinacea during pregnancy. However, the evidence package is limited by small sample sizes, reliance on self‑reported use, lack of exposure characterisation and potential confounding factors such as underlying maternal health status, concomitant medication use, smoking status, alcohol consumption, maternal age, body mass index (BMI) and other lifestyle factors. While some studies adjusted for a number of these confounding factors, adjustment was not consistent across studies and residual confounding cannot be excluded.

46. A prospective controlled study by Gallo et al. (2000) has assessed the safety of Echinacea use during pregnancy. The study group – 206 pregnant women who were enrolled and followed up prospectively after contacting the Motherisk Program – was matched to a control group by disease (upper respiratory tract ailments), maternal age (±2 years), alcohol use and cigarette smoking. The control group consisted of pregnant women who had contacted the Motherisk Programme regarding the safety of Echinacea for an upper respiratory tract ailment but subsequently did not use Echinacea. Some went on to use a nonteratogenic antibiotic. In the study group, 112/206 women (54%) used Echinacea in the first trimester and 17/206 (8%) were exposed in all 3 trimesters. A total of 114/198 (58%) respondents used capsule or tablet preparations, or both, of Echinacea (250 to 1000 mg/d); 76/198 (38%) of the subjects used tinctures (5 to 30 drops per day). Exposure information was only available for 198 of the 206 women enrolled in the study. The self-reported duration of use was between 5 and 7 days. Different brands of E. purpurea and E. angustifolia were used, but the number of women using each species was not specified; E. pallida was only used by one woman. The study reported no significant differences between Echinacea users and controls in terms of pregnancy outcomes, including birth weight, gestational age, or malformation rates. Among Echinacea users, there were 195 live births (including three sets of twins), 13 spontaneous abortions, and 1 therapeutic abortion; the control group had similar outcomes (198 live births, 7 spontaneous abortions, and 1 therapeutic abortion). The authors stated that the malformation rates between Echinacea users and controls were also comparable, leading them to conclude that Echinacea use during organogenesis did not increase the occurrence of major malformations.

47. Heitmann et al. (2016) conducted a large prospective cohort study within the Norwegian Mother and Child Cohort, including 68,522 pregnancies after exclusion of multiple births and chromosomal abnormalities. Maternal characteristics and potential confounders such as age, pre pregnancy basal metabolic index, folic acid use, smoking, education, previous pregnancy loss and year of delivery were adjusted for in the analyses using generalised estimating equations (GEE) models. Among the participants, 363 women (0.5%) reported using Echinacea during pregnancy, most commonly for treatment of respiratory tract infections. Echinacea supplements were taken during early (206 women) and late (183 women) pregnancy, with figures including women who reported use during both periods. Timing details for individual exposers were limited, and information on dosage and preparation was not available. The study reported no increased risk of adverse maternal or pregnancy outcomes in Echinacea users, and users did not show higher rates of preterm birth, low birth weight, or delivery of small for gestational age infants.

48. The study by Heitmann et al. (2016) assessed the frequency of all malformations, major malformations and cardiovascular malformations. All malformations included any congenital anomaly recorded in the Medical Birth Registry of Norway. Major malformations were defined according to the European Surveillance of Congenital Anomalies (EUROCAT) classification system as congenital anomalies with serious medical, surgical, functional or cosmetic consequences (EUROCAT, 2014). Cardiovascular malformations comprised congenital heart and great vessel defects classified under the EUROCAT system (EUROCAT, 2014). No increased risk of all malformations (adjusted OR [95% CI] = 1.1 [0.6-2.1]), major malformations (adjusted OR [95% CI] = 0.6 [0.2-1.8]) or cardiovascular malformations (adjusted OR [95% CI] = 0.6 [0.1-4.3]) was detected amongst women who had used Echinacea during early pregnancy compared with controls.

49. Cuzzolin et al. (2010) conducted a 10‑month survey of 392 Italian women in maternity wards using structured, face‑to‑face interviews to collect information on herbal product use during pregnancy, maternal health history and newborn outcomes. A total of 109 women (27.8%) reported using at least one herbal remedy during pregnancy; 37.8% of them had used herbal products throughout gestation. Echinacea was used orally by 10 women (9.2% of herbal users) for colds, anxiety, and immune support. No details on species, plant part, preparation type, dosage, timing or duration were provided. By examining each herb descriptively, the authors reported one case in which prolonged Echinacea intake was possibly associated with intrauterine growth restriction in a 35 week newborn, although no further clinical details were provided for that case. The authors noted that the sample size limited the statistical analysis, resulting in all herbal products being treated as a single exposure group without distinguishing individual herbs and their separate effects on pregnancy outcomes.

50. To investigate the use of herbal medicines in pregnant women in relation to pregnancy outcomes, Nordeng et al. (2011) administered a structured questionnaire to 600 women within five days after delivery at Stavanger University Hospital, Norway. In this cohort, 40% of women reported using herbal medicines during pregnancy. Out of the 600 women interviewed, 45 (7.5%) reported using Echinacea during pregnancy to treat cold and flu symptoms. No details were provided on Echinacea species, dosage, or timing. In their analysis, the authors evaluated potential confounding factors through multivariable linear and logistic regression models, adjusting for maternal age, parity, education, marital status, gestational length, and conventional drug use, although some important confounders such as smoking and pre pregnancy BMI were not available. In this study, Echinacea use during pregnancy was not associated with adverse effects on birthweight, gestational age, mode of delivery, or neonatal complications.

Lactation

51. A case study examined the bioavailability of Echinacea alkylamides in human breast milk in a 35 year old volunteer at six different time points after ingestion of four Echinacea Premium tablets (Matthias et al., 2008). The tablets were prepared from dried ethanolic extracts of two Echinacea species and each tablet contained the equivalent of 675 mg E. purpurea root and 600 mg E. angustifolia root. A total of 13.1 mg of N-isobutyldodeca-2E,4E,8Z,10E/Z-tetraenamide alkylamides were ingested by the volunteer and they were found in the breast milk between 1 and 4 hours after the administration of the Echinacea tablets. Further details were not present in this conference abstract.

Maternal life history stages covered by reproductive and developmental studies

52. In order to identify any data gaps within the reproductive and developmental window when considering the safety of Echinacea in the maternal diet, the maternal life history stages covered by the animal and human studies discussed above are summarised in Table 1. Further information on the maternal life history stages, including their definition, can be found in the Scope of the Nutrition and maternal health project Annex. The terms insufficient, limited and adequate are used to describe the degree to which the study addresses and provides relevant data for the specific maternal life history stage. It must be noted that none of the studies are compliant with OECD guidelines.

Table 1. Maternal life history stages covered by available Echinacea animal and human studies

Study reference Study type Echinacea preparation and dose Stage A (pre-mating to conception) Stage B (conception to implantation) Stage C (implantation to parturition - pregnancy) Stage D (post-partum including lactation)
Chow et al. 2006 Animal study (DBA/2 mice) E. purpurea extract 0.45 mg/kg bw/day (dose per body weight) Insufficient Limited Limited Insufficient
Barcz et al. 2007 Animal study (Balb/c mice) E. purpurea extract 0.6 mg/day Insufficient Limited Limited Insufficient
Maass et al., 2005) Animal study (pigs) E. purpurea dried cobs 1.2–3.6% gestation diet at 2.6 kg/day; 0.5–1.5% lactation diet at to 6 kg/day Insufficient Insufficient Limited Adequate
Dabbou et al., 2016 Animal study (rabbits) E. pallida 3 g/kg Insufficient Adequate Adequate Adequate
Kovitvadhi et al., 2016 Animal study (rabbits) E. pallida 3 g/kg Insufficient Insufficient Insufficient Adequate
Gallo et al., 2000 Human prospective controlled study E. purpurea and E. angustifolia 250- 1000 mg/day Insufficient Insufficient Limited Insufficient
Heitmann et al., 2016 Human prospective cohort study Not specified Insufficient Insufficient Limited Insufficient
Cuzzolin et al., 2010 Human cross-sectional study Not specified Insufficient Insufficient Limited Insufficient
Nordeng et al., 2011 Human cross-sectional study Not specified Insufficient Insufficient Limited Insufficient
Matthias et al., 2008 Human case report Four tablets each containing E. purpurea 675 mg and E. angustifolia 600 mg Insufficient Insufficient Insufficient Limited

*The terms insufficient, limited, and adequate indicate the degree to which the study addresses and provides relevant data for the specific maternal life history stage.

Toxicity Studies

Cytotoxicity

E. purpurea

53. Tsai et al. (2012a) investigated the cytotoxicity of E. purpurea flower extract and its bioactive constituent chicoric acid in human colorectal cancer cell lines (HCT-116 and Caco-2). Treatment with Echinacea extract (0 – 2,000 μg/mL) for 24 hours did not affect cell viability, but a dose-dependent reduction was observed at 48 hours. Chicoric acid significantly decreased cell viability at ≥150 μg/mL after 24 hours and at all tested concentrations (50–200 μg/mL) after 48 hours. In HCT-116 cells, chicoric acid (50–150 μg/mL) suppressed telomerase activity, induced DNA fragmentation, activated caspase-9, and promoted poly(ADP-ribose) polymerase (PARP) cleavage, indicating apoptosis. The authors concluded that the possible in vitro cytotoxicity mechanism of E. purpurea extract is mediated by repression of telomerase activity, activation of caspase pathway and induction of apoptosis.

E. angustifolia

54. The cytotoxicity of an ethyl acetate extract of E. angustifolia was evaluated against two cancer cell lines MDA-MB-231 (ATCC HTB-26) and MCF-7 (ATCC HTB-22) and a healthy breast epithelial cell line MCF-10 (ATCC) using an 3-4,5-dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assay (Espinosa-Paredes et al., 2021). The extract contained 11.2 µg/mg echinacoside and 8.18 µg/mg caffeic acid. The study reported that the E. angustifolia extract showed no cytotoxicity toward healthy MCF 10 cells, whereas it reduced cell viability in both cancer cell lines. Calculated IC₅₀ values lay between 16.3 and 28.8 µg/mL and did not differ significantly between 24 and 48 hour time points. The study also concluded that the E. angustifolia extract induced cell cycle arrest in the G1 phase and caspase-mediated apoptosis.

Acute toxicity

E. purpurea

55. A single high dose study reported no deaths or signs of toxicity following oral or intravenous administration of E. purpurea expressed juice to Wistar rats and NMRI mice (Mengs et al., 1991). No abnormalities were seen during a 14 day observation period or during necropsy, and an LD₅₀ could not be determined.

E. angustifolia

56. An OECD TG 432-compliant single dose study reported no clinical signs, mortality, or macroscopic lesions after the administration of 2,000 mg/kg bw of E. angustifolia ethyl acetate extract to three male CD-1 mice (Espinosa-Paredes et al., 2021). The extract contained 11.2 µg/mg echinacoside and 8.18 µg/mg caffeic acid.

Sub-acute toxicity

E. purpurea

57. Expressed juice from E. purpurea was administered via oral gavage to groups of 18 Wistar rats per sex at doses of 0, 800, 2,400 or 8,000 mg/kg body weight daily for four weeks (Mengs et al., 1991). A statistically significant reduction in plasma alkaline phosphatase was observed in males at 2,400 and 8,000 mg/kg, while females exhibited a significant increase in prothrombin time at the same dose levels compared to controls. The authors concluded that, since the alkaline phosphatase and prothrombin time were still in the normal physiological variation range for the rat strain used and there was no dose dependent response, no toxicological point of departure could be derived from the data. The study reported that other parameters, including biochemical and haematological results, body weight, food consumption, ophthalmological findings, necropsy, and histopathology, showed no significant differences among treatment groups. The authors claimed compliance with OECD GLP guidelines and OECD recommendations for technical methods, although no specific OECD TG applicable to the subacute toxicity study was referenced.

E. angustifolia

58. Espinosa-Paredes et al. (2021) conducted a 28-day repeated-dose toxicity study with ethyl acetate extract of E. angustifolia. The extract, containing 11.2 µg/mg echinacoside and 8.18 µg/mg caffeic acid, was administered to five CD-1 mice per dose per sex at 20 mg/kg bw or 200 mg/kg bw in accordance with the OECD TG 407. Serum aspartate aminotransferase, alanine aminotransferase and creatinine levels were determined. No statistically significant differences were observed between treated and control groups. The authors concluded that there was no evidence of liver or kidney toxicity associated with the E. angustifolia extract.

Sub-chronic toxicity

E. purpurea

59. The toxicity of E. purpurea extract was evaluated in a 13-week repeated oral dose toxicity test in Sprague Dawley rats (Jeong et al., 2024). The study was conducted in accordance with GLP regulations and Test Guidelines of Standards for Toxicity Studies of Drugs issued by the Korean Food and Drug Administration. The E. purpurea extract, standardised to contain at least 2% chicoric acid, was administered daily at doses of 0, 500, 1,000, and 2,000 mg/kg body weight to groups of 10 rats per sex. No mortality or abnormal clinical signs were observed in either sex at any of the tested doses. The study reported that ophthalmological examinations, absolute and relative organ weights, haematology, and serum biochemistry showed no significant differences between treated and control groups. Urinalysis revealed a statistically significant increase in mean urine volume in males at 1,000 mg/kg compared to controls. Some individual variations were also observed in the urinalysis, but the study concluded they were not significantly different when compared to the controls.

Genotoxicity

E. purpurea

In vitro genotoxicity assays
Bacterial reverse mutation tests

60. A lyophilised Echinacin Liquidum herbal medicinal product (E. purpurea) was evaluated for mutagenic potential in an in vitro bacterial reverse mutation assay using Salmonella typhimurium strains TA98, TA100, TA1535, TA1537 and TA1538, with and without S9 metabolic activation, at concentrations ranging from 8 to 5,000 µg/plate (Mengs et al., 1991). The test material, the bacterial strains and S9 mix were incorporated into molten agar, poured onto minimal agar plates and incubated at 37°C for three days. The authors reported that across three replicates, mean revertant counts showed no reproducible, statistically significant or dose related increases in any strain, with or without metabolic activation. Since no positive response was observed at any concentration up to the limit dose of 5,000 µg/plate, the study concluded that the tested product exhibited no mutagenic potential. The study stated compliance with GLP and OECD technical recommendations, although no specific OECD TG applicable to the bacterial reverse mutation test was referenced.

61. The mutagenicity and antimutagenic effects of freeze dried E. purpurea 50% ethanolic extracts were evaluated in S. typhimurium TA98 and TA100 strains with and without S9 metabolic activation at a maximum concentration of 5,000 µg/plate (Tsai et al., 2012b). The ethanolic extracts contained caftaric acid, chlorogenic acid, echinacoside and cichoric acid, but no cynarin. For the mutagenicity assay, the bacteria were mixed with 250 - 5,000 µg/plate of the extract, incubated on histidine containing media at 37°C for 48 h and revertant colonies were compared with vehicle controls. The study reported that the E. purpurea extract did not induce any significant increases in revertant numbers in either strain, at any concentration under any condition, when compared to control plates treated with dimethyl sulfoxide (DMSO). The authors also assessed antimutagenic activity of the extract by calculating the percentage inhibition of the reversion rate in the presence of 2 aminoanthracene and reported that the E. purpurea extract demonstrated a dose dependent inhibitory effect on 2 aminoanthracene induced mutagenicity in both S. typhimurium strains. There was no indication as to whether the bacterial reverse mutation test had been conducted in compliance with OECD TGs.

62. E. purpurea extract standardised to contain at least 2% chicoric acid was tested in an in vitro bacterial reverse mutation test in S. typhimurium strains TA98, TA100, TA1535 and TA1537 and tryptophan auxotroph mutant Escherichia coli strain (WP2uvrA) in accordance with OECD TG 471 (Jeong et al., 2024). The bacterial strains were incubated with the E. purpurea extract at up to 5,000 µg/plate with and without S9 mix, for 48 hours at 37°C. Sodium azide, 2-nitrofluorene, 2-aminoanthracene, aminoacridine and 4-nitroquinoline N-oxide were used as positive controls and water was used as negative control. The authors stated that the number of mutant colonies at all doses of test compound for each strain did not exceed twice that of the negative control and results were considered negative for mutagenicity.

Mouse lymphoma assay

63. A lyophilised Echinacin Liquidum herbal medicinal product (E. purpurea) was evaluated for its potential to induce mutations at the hypoxanthine phosphoribosyltransferase (HPRT) locus of L5178Y mouse lymphoma cells, both in the presence and absence of S9 metabolic activation, at concentrations ranging from 50 to 5,000 µg/mL (Mengs et al., 1991). The cells were exposed to the test or control solution for 2 hours, then allowed a 7 day expression period before plating with and without 6 thioguanine to determine mutation frequency. A response was considered significant only if treated cultures exceeded the 95th percentile threshold of controls, occurred at consecutive doses, and showed a dose response by regression analysis. Cytotoxicity was assessed via plating efficiency immediately after treatment. Echinacea treatment did not produce a statistically significant increase in mutation frequency at any of the concentrations tested, with or without S9 metabolic activation; doses up to 5,000 µg/mL were considered essentially non toxic. The study stated compliance with the GLP and OECD technical recommendations, although no specific OECD TG applicable to the mouse lymphoma assay were referenced.

Chromosomal aberration tests

64. Mengs et al. (1991) also tested the lyophilised Echinacin Liquidum herbal medicinal product (E. purpurea) in an in vitro cytogenetic assay using human lymphocyte cultures, with and without S9 metabolic activation, at concentrations ranging from 2,400 to 5,000 µg/mL. The cells were exposed to the test or control solution for either 20 or 44 hours (without S9) or for 3 hours followed by recovery (with S9), then analysed for mitotic index and chromosomal aberrations. The authors stated that no mitotic inhibition was observed at any concentration under any condition. A small but statistically significant increase in the proportion of cells with structural chromosomal aberrations was reported at 5,000 µg/mL at the 20 hour sample point without S9. However, the authors considered this biologically insignificant because values remained within the laboratory’s normal range and coincided with increased osmolality of the treatment medium. The study stated compliance with GLP and OECD technical recommendations, although no specific OECD TG applicable to the chromosome aberration assay were referenced.

65. E. purpurea extract standardised to contain at least 2% chicoric acid was tested in an in vitro chromosomal aberration test using Chinese Hamster Lung (CHL/IU) cells in accordance with OECD TG 473 (Jeong et al., 2024). The cells were incubated with the E. purpurea extract at concentrations of 78.1, 156 and 313 µg/mL, in the presence or absence of S9, for either 6 or 24 hours for the short-term and continuous treatment, respectively. Mitomycin C at a concentration of 0.1 μg/mL and benzo[a]pyrene at 20 μg/mL were used as positive controls, whilst water was used as the negative control. Microscopic slides for chromosomal observation were prepared, and chromosomal abnormalities were divided into structural and numerical aberrations. The study reported that no statistically significant increase in structural or numerical chromosomal aberrations was observed in the Echinacea treated cells compared to controls at any of the concentrations tested, with or without S9 metabolic activation.

In vivo micronucleus test

66. Mengs et al. (1991) conducted an in vivo micronucleus test using a single oral dose of 25,000 mg/kg Echinacin Liquidum (E. purpurea) via oral gavage to groups of 5 male and 5 female NMRI mice. The animals were sacrificed at either 24, 48 or 72 hours after the dose. Positive control groups received 100 mg/kg cyclophosphamide via intraperitoneal injection, and negative controls received 25 mL/kg water by oral gavage. Bone marrow was collected from the femur, and two smears per animal were prepared, fixed, and stained. One thousand polychromatic erythrocytes (PCE) per animal were scored microscopically for micronuclei. The authors reported that the positive control showed a significant increase in the proportion of micronucleated PCE, whilst the Echinacea preparation did not show any statistically significant differences compared to the negative control. The PCE/NCE ratio was also not significantly different between treated and control groups. The study stated compliance with GLP and applicable OECD technical recommendations, although it did not reference a specific OECD TG for the in vivo micronucleus test. Additionally, no toxicokinetic measurements were reported to demonstrate bone marrow exposure to the test substance.

67. E. purpurea extract standardised to contain at least 2% chicoric acid was orally administered at 1,250, 2,500 and 5,000 mg/kg bw to seven-week-old male Sprague Dawley rats (5 animals per group) in an in vivo micronucleus test in accordance with OECD TG 474 (Jeong et al., 2024). Positive control groups received 20 mg/kg cyclophosphamide orally, and negative controls received water. Following the second dosing, bone marrow was collected from the femurs, fixed, and stained with acridine orange for fluorescence microscopy. Genotoxicity was assessed by counting micronucleated PCEs among 4,000 PCE per rat, and cytotoxicity was evaluated based on the proportion of PCE among 500 red blood cells. Cytotoxicity indices were comparable across all groups. The study reported that the positive control produced a genotoxicity index approximately 100‑fold higher than the negative control, whilst none of the Echinacea dose groups showed statistically significant differences in genotoxicity relative to the negative control. Toxicokinetic measurements with pure chicoric acid and the standardised E. purpurea extract were also performed to demonstrate systemic exposure to the test substance. For further details of the toxicokinetic study see paragraph 24.

E. angustifolia

68. Espinosa-Paredes et al. (2021) conducted an in vitro bacterial reverse mutation test and an in vivo micronucleus test with E. angustifolia ethyl acetate extract containing 11.2 µg/mg echinacoside and 8.18 µg/mg caffeic acid. There is no indication as to whether these tests had been performed in accordance with the OECD TG.

69. For the bacterial reverse mutation assay, the bacterial strains S. typhimurium TA98, TA100 and TA102 were incubated with the E. angustifolia extract at up to 200 µg/plate, with and without S9 mix, for 48 hours at 37°C. Picrolonic acid, 2-amino-anthracene, N-methyl-N′-nitro-N-nitrosoguanidine and mitomycin-C were used as positive controls, the negative (vehicle) control was DMSO. A test was considered positive when the number of spontaneous colonies exceeded twice the number of basal revertants. The authors reported that the tested concentrations of E. angustifolia extract, with or without S9 mix, did not yield a positive result and concluded no genotoxic activity was therefore observed.

70. For the in vivo micronucleus test, the E. angustifolia extract was administered intragastrically at 1,000 mg/kg bw to three male CD-1 mice. DMSO was used as a vehicle control, water as the negative control and cyclophosphamide (50 mg/kg) as the positive control. The animals were euthanised 48 hours after test substance administration, blood samples were collected, fixed and labelled prior to flow cytometry analysis. The frequencies of normochromatic erythrocytes and reticulocytes with and without micronuclei were evaluated in order to calculate the percentages of mature normochromatic erythrocytes, micronucleated reticulocytes and total reticulocytes. E. angustifolia extract did not induce a significant increase in micronucleus formation, the frequency of micronucleated reticulocytes in treated mice being 0.9% vs 0.3% in the negative controls. A decrease in the frequency of RETs in the Echinacea extract group compared with the negative controls (2.56 % vs 5.41 %, p < 0.05) was reported, but the authors did not comment on its biological relevance. No toxicokinetic measurements were reported to demonstrate bone marrow exposure to the test substance. Adverse effects in humans

71. The adverse effects of Echinacea preparations in humans have been described in several literature reviews, EMA assessment reports, individual case studies and pharmacovigilance data. Although these findings relate to the general population and not specifically to pregnant women or exposure through the maternal diet, they have been included to provide broader insight into the potential toxicities of Echinacea in humans, while acknowledging their limited relevance to pregnancy-specific risk assessment.

72. The EMA assessment report on E. purpurea concluded that, based on the analysis of pharmacovigilance reports from EU member states, possible adverse effects included hypersensitivity reactions such as rash, urticaria, itching and swelling and, in one case, an allergic reaction. In these circumstances Echinacea should not be taken again. The EMA report noted cases of severe reactions such as Stevens-Johnson Syndrome, angioedema, bronchospasm, asthma and anaphylactic shock with confirmed/probable causality. Cases of autoimmune diseases such as encephalitis disseminata, erythema nodosum, immunothrombocytopenia and Sjögren’s syndrome with renal tubular dysfunction were reported, but their causality was inconclusive. Reported gastrointestinal side effects were considered unlikely to be linked to Echinacea because their frequency was similar between the placebo and treatment groups in clinical trials (EMA, 2014).

73. A meta-analysis of six randomised controlled trials evaluating various Echinacea preparations for respiratory tract infections also reported on adverse events in 1,440 Echinacea-treated participants and 1,326 placebo-treated controls (Schapowal et al., 2015). Although the trials primarily assessed potential benefits, the safety data indicated no significant difference in the overall number of adverse events between Echinacea (491 events) and placebo (474 events). The Echinacea products used varied across studies; they included ethanol/glycerol extracts of E. purpurea and E. angustifolia (500–4,000 mg extract/day) and pressed juices of E. purpurea (6,200–10,000 mg/day). Most reported adverse effects were mild, transient gastrointestinal disturbances. Two severe adverse events (stridor) occurred in the Echinacea group, and one severe event (glandular fever requiring hospitalisation) occurred in the placebo group. No significant differences in clinical biochemistry were observed. The meta-analysis concluded that Echinacea may reduce respiratory tract infections, but these findings are beyond the scope of the present assessment and the safety data are considered here to inform understanding of potential adverse effects associated with Echinacea use in humans.

74. A systematic review by Huntley et al. (2005) summarised evidence of the safety of Echinacea-based herbal medicinal products from 36 clinical studies, case reports, and spontaneous reporting programmes from regulatory agencies in Australia, Germany, UK, USA and Sweden. The oral doses used in the clinical trials were typically 4-8 mL expressed juice/liquid extract twice daily, 250-1,000 mg daily in the form of capsules/tablets or 5-30 drops daily for the tinctures. The review concluded that Echinacea had a good safety profile when taken in the short term, short-term use being defined as ‘days as opposed to weeks’. Reported adverse effects, the commonest of which were gastrointestinal disturbances and skin-related reactions, were mild, transient and reversible. The review discussed that in rare cases Echinacea use can be associated with allergic reactions, which can be severe. However, the authors noted that in about a quarter of these cases, Echinacin ® (E. purpurea) was administered via intramuscular or intravenous routes. Nevertheless, the authors suggested that atopic and asthmatic patients should be cautious when using Echinacea supplements.

75. An Australian study reviewed 51 reports of adverse drug reactions (ADRs) associated with Echinacea in the Australian Adverse Drug Reactions Advisory Committee’s database (Mullins and Heddle, 2002). Of these, 26 were suggestive of IgE-mediated hypersensitivity reactions (4 anaphylaxis, 12 acute asthma,10 urticaria/angioedema). Seventy eight percent of the affected patients were female, the median age was 32 years and over half had a history of asthma, allergic rhinitis or atopic dermatitis. In addition to the review of the ADR reports, five cases of adverse reactions to Echinacea were personally evaluated by the authors. Two patients suffered anaphylaxis and a third had an acute asthma attack 10 minutes after their first ever dose of Echinacea. All three patients were female, had a history of atopy including allergic rhinitis or latex allergy and tested positive on skin prick tests to aqueous Echinacea. A fourth case described a 56-year-old man who developed recurrent mild asthma with Echinacea tablets, resolving upon discontinuation. The fifth case involved a 48-year-old woman who developed a maculopapular rash within two days of Echinacea tablets ingestion, recurring on rechallenge. Both latter patients had allergic rhinitis but negative skin prick test. The overall conclusion of the study was that there is a possible cross-reactivity between Echinacea and other environmental allergens, and that atopic patients should be warned accordingly (Mullins and Heddle, 2002).

76. Individual case reports of adverse effects experienced by people after taking Echinacea preparations include an autoimmune disease supposedly triggered by Echinacea (Lee and Werth, 2004), an isolated case of erythema nodosum in a 41-year old male (Lee Soon and Crawford, 2001), hypereosinophilia in a 58-year old male patient with history of asthma and allergic rhinitis (Maskatia and Baker, 2010), leucopenia in a 51 year old woman who took 450 mg Echinacea capsules for 2 months (Kemp and Franco, 2002), thrombocytopenia with E. pallida in a 32 year old man (George et al., 2006) and hepatotoxicity in a 45-year old male who took 1,500 mg Echinacea root for the treatment of cold (Kocaman et al., 2008). However, these case reports contain limited information about the doses taken, and there is uncertainty as to whether the adverse effects described were related to Echinacea consumption or to other factors, including the use of other herbal products such as St John’s Wort (Lee Soon and Crawford, 2001) or Gingko biloba (Kemp and Franco, 2002). A single reported case of hepatotoxicity associated with Echinacea was identified as Echinacea-induced acute cholestatic autoimmune hepatitis due to the immunostimulatory effects of Echinacea (Kocaman et al., 2008). Duration of use

77. The EMA advises that oral Echinacea preparations should be used for a limited duration of up to 10 days (EMA, 2014). The German Commission E monographs on Echinacea recommend that internal and external administration of E. purpurea and E. pallida should not exceed 8 weeks (Blumenthal et al., 1999). Some clinical studies (see paragraphs 72–74) report the use of Echinacea preparations for longer periods but it should be noted that these typically involve medicinal Echinacea preparations which may not be directly comparable to the foods or food supplements that are the focus of this assessment.

78. Clinical studies of varying durations from 4-21 days to 4-12 weeks involving Echinacea have been reported (Ardjomand-Woelkart and Bauer, 2015). The study with the longest duration was a prospective, placebo controlled, double blind cross over trial in which participants (n=50) were randomised to receive 6 months of 800 mg Echinaforce (95% E. purpurea whole plant extract and 5% E. purpurea root extract) twice daily or placebo, followed by the alternate treatment for a further 6 months, for reducing the frequency and duration of recurrent genital herpes (Vonau et al., 2001). The only side effects reported were nausea (n = 4) and diarrhoea (n = 2). Pregnancy, or not using effective contraception during the study period, were exclusion criteria for this trial.

79. The use of E. purpurea and E. angustifolia root liquid extract for 12 weeks (100 drops daily of a 1:11, 30% ethanolic extract for 5 days a week) was studied in a randomised, double-blind placebo controlled trial involving 289 patients (n=100 for E. angustifolia, n=99 for E. purpurea, n=90 for placebo) for the prevention of respiratory tract infections (Melchart, 1998). The side effects reported included minor gastrointestinal symptoms, headache/dizziness and allergic reactions; they were similar between the treatment arm and placebo (Melchart, 1998).

80. The safety and efficacy of Echinaforce has been tested over 4 months in a large randomised, double-blind, placebo-controlled clinical trial (Jawad et al., 2012). A total of 755 subjects were included; the main criterion for inclusion was experiencing ≥2 colds per year. Participants took the equivalent of 2,400 mg of extract a day for illness prevention and during acute stages of colds the dose was increased to 4,000 mg extract/day. There were no significant differences between the frequencies and the type of adverse effects between treatment and placebo. Haematological and biochemical measures were not significantly different before and after Echinacea treatment and when compared to placebo.

Mechanism of action

81. The mechanism of action of Echinacea preparations in relation to common cold symptoms is not known. The antiviral, immunomodulatory and anti-inflammatory effects of Echinacea reported in in vitro, in vivo and in human studies are referenced below. However, the relevance of the in vitro and in vivo effects of Echinacea to clinical efficacy is not known and the pharmacodynamic mechanism involved cannot be established (EMA, 2014).

Antiviral effects

82. The mechanism of the antiviral action of Echinacea has not been fully elucidated but is thought to be due to prevention of viral entry into the cells rather than inhibition of viral replication (Pleschka et al., 2009; Sharma et al., 2009), suggesting that Echinacea treatment is effective only at the very early stages in the infection process (Pleschka et al., 2009). The use of different species, extraction methods and preparations make it difficult to attribute the antiviral activity of Echinacea to specific compounds.

Immunomodulatory and anti-inflammatory effects

83. The immunomodulatory properties of Echinacea and its constituents have been extensively studied and reviewed in the literature (Table 2). The majority of studies focused on E. purpurea preparations, with the exception of Zhao et al. (2007) where E. angustifolia and E. pallida were also tested. The studies reviewed in this statement reported that Echinacea stimulated the secretion of TNF-α (Burger et al., 1997; Rinninger et al., 2002; Goel et al., 2002), IL-1 (Burger et al., 1997; Rinninger et al., 2002; Zhai et al., 2007) and IL-10 (Burger et al., 1997; Li et al., 2017) from macrophages and IFN-γ from lymphocytes (Li et al., 2017; Zhao et al. 2007). Echinacea has also been shown to increase natural killer cell (NK)-mediated cytotoxicity (See et al., 1997; Gan et al., 2003; Zhao et al. 2007), promote dendritic cell maturation (Li et al., 2017) and lead to changes in the percentage of immune cell populations, including T lymphocytes and NK cells (Zhao et al. 2007; Li et al., 2017; Gan et al., 2003). Echinacea has also been reported to inhibit the induction of pro-inflammatory cytokines IL-6, IL-8 and TNF-α in vitro (Sharma et al., 2009) and IL-10 and IFN-γ in vivo (Fusco et al., 2010). The authors suggested that this immunomodulatory activity may contribute to improved clinical outcomes by moderating the inflammatory response (Fusco et al., 2010).

84. Echinacea extracts have also been reported to exhibit anti-inflammatory properties due to their ability to inhibit cyclooxygenases (COX) I and COX II (Clifford et al., 2002) and 5-lipoxygenase (5-LOX) (Merali et al., 2003). Clifford et al. (2002) found that alkylamides from E. purpurea roots inhibited COX-I and COX-II by 36–60% and 15–46%, respectively, at 100 µg/mL, compared to higher inhibition by standard non-steroidal anti-inflammatory drugs (NSAIDs). Merali et al. (2003) reported 5-LOX inhibition by root extracts of E. angustifolia, E. purpurea, and E. pallida attributing the activity to the presence of alkylamides in the extracts.

Table 2. Summary of the immunomodulatory effects of Echinacea

Echinacea preparation Concentration or dose Test system Treatment duration Summary of immune system effects Reference
Fresh and dried juice from EchinaFresh (E. purpurea) standardized for a content of 2.4% soluble β-1,2-D-fructofuranosides. 0.05-10 µg/mL fresh juice and 0.01-10 µg/mL dried juice. Human peripheral blood macrophages Cells treated for 18 hours prior to IL-1 determination, and for 36 and 72 hours prior to analysis for TNF-α, IL-6 and IL-10. Statistically significant increase in the production of IL-1, TNF-α, IL-6 and IL-10 by the macrophages at all concentrations of Echinacea. Burger et al., 1997
E. purpurea raw herb and root powders subjected to a simulated digestion protocol in simulated gastric fluid. 5 – 320 µg/mL RAW267.7 murine macrophages Cells treated for 24, 30 and 48 hours prior to analysis. Dose dependent induction of TNF-α,nitric oxide(NO), IL-1α, IL-1β, and IL-6 with Echinacea treatment comparable to the results observed with the LPS positive control. Rinninger et al., 2002
Plant parts extracted with aqueous ethanol, producing four different fractions with concentrations of chicoric acid, polysaccharide and alkylamides at basal level, 3, 20 and 50 times the basal level. 100 µL via oral gavage Male Sprague-Dawley rats Doses administrated twice a day for 4 days. Echinacea fractions at 20 and 50 times the basal dose levels significantly increased the phagocytic index in alveolar macrophages compared to basal and 3 times basal level dose. TNF-α secretion from alveolar macrophages showed a dose-dependent rise with 3- and 20-times basal level doses. Similarly, spleen macrophages exhibited dose-dependent increases in TNF-α and IFN-γ release. Goel et al., 2002
Commercially available E. purpurea extracts with a defined chemical composition of chicoric acid (3.045%), caftaric acid (1.575%), chlorogenic acid (0.065%), dodeca-2E, 4E, 8Z, 10E/Z-tetraenoic acid isobutylamide (1.635%) 400 μg/mL Bone marrow-derived dendritic cells (BMDCs) derived from femur and tibia of 6–8-week-old female C57BL/6 mice Cells treated for 48 hours prior to analysis. Echinacea treatment significantly increased percentage of CD40, CD80, CD83 and CD86 markers on BMDCs and increased the secretion of IFN-γ, IL-12, IL-10, and TGF-β1 by BMDCs. Endocytosis of fluorescently labelled dextran reduced by Echinacea treatment, similar to results observed with LPS control. Li et al., 2017
Dried, ground preparations of fresh E. purpurea herb homogenized, filtered and used fresh the same day. 0.001 to 1000 pg/mL Human peripheral blood mononuclear cells (PBMC) from healthy patients or patients with chronic fatigue syndrome (CFS) or acquired immunodeficiency syndrome (AIDS) Cells treated for 4 hours prior to analysis. Significant increase in the NK cell activity from healthy patients and those with CFS and AIDS was observed following Echinacea treatment in a concentration dependent manner. A similar concentration dependent response was observed for the antibody dependent cell-mediated cytotoxicity in all three patient groups following E. purpurea treatment. See et al., 1997
E. purpurea dissolved in water and filtered to prepare a water-soluble extract. Concentrations up to 10 µg/mL Human peripheral blood mononuclear cells (PBMC) Cells were treated by overnight incubation prior to analysis. Increase in the NK-mediated cytotoxic activity was observed with E. purpurea treatment in a concentration dependent manner. Echinacea treatment reduced CD16 expression (frequency and intensity) by lymphocytes, while increasing CD69 expression within CD16⁺ populations, with over 90% CD16⁺ cells expressing CD69 at the highest concentration. Gan et al., 2003
Ground E. purpurea aerial parts and freeze dried into a powder. The preparation contained cichoric and caftaric acids, as well as cynarin, but not alkylamide. Concentrations of up to 250 μg/mL Human T-cell line Jurkat E6-1 Cells were treated for 24 hours prior to analysis. E. purpurea induced a dose-dependent increase in IL-2 secretion and a five-fold rise of IFN-γ secretion by high-density T cells. Fonseca et al., 2014
Alcohol extracts of Echinacea. E. purpurea contained chicoric acid and caftaric acid, no echinacoside. E. angustifolia contained echiancoside, cynarin, chlorogenic acid. E. pallida contained echinacoside, chlorogenic acid and caftaric acid. 130 mg/kg bw/day by gavage Eight-week-old male BALB/c mice Doses administered once daily for 7 days. All three Echinacea species increased IFN-γ production in mitogen-stimulated splenocytes, suppressed IL-1β and TNF-α. In non-stimulated splenocytes, E. purpurea significantly increased IL-1β secretion. E. purpurea increased the percentage of CD49⁺ and CD19⁺ splenic cells, while E. angustifolia only increased CD49⁺; E. pallida had no effect on either. Only E. pallida significantly enhanced NK cell cytotoxicity. Zhao et al., 2007

Contaminants

85. Very few studies, described below, have investigated potential contaminants in Echinacea preparations, including heavy metals, moulds and mycotoxins.

86. During the 1999-2004 round of the US National Health and Nutrition Examination Survey (NHANES), 13,504 adults participated in interviews and examinations and had their blood lead levels assessed (Buettner et al., 2009). A regression model for women of child-bearing age (16-45 years) indicated that those who used herbal supplements had adjusted blood lead levels 20% (95% CI 5%–34%, p = 0.008) higher than women who did not. However, when broken down by the specific herbal supplement, the difference was not significant for Echinacea supplements (8%, 95% CI -15% – 35%, p = 0.55).

87. Filipiak-Szok et al., (2015) measured concentrations of heavy metals, including lead (Pb), cadmium (Cd), arsenic (As), aluminium (Al), nickel (Ni), barium (Ba), and antimony (Sb), in raw plant material of selected medicinally used herbs and dietary supplements available on the Polish market. These results were compared against the limits set by WHO (0.3 mg/kg for cadmium, 10 mg/kg for lead and 5.0 mg/kg for arsenic) and by the EU Commission Regulation (EC) No. 1881/2006 (1.0 mg/kg for cadmium and 3.0 mg/kg for lead). The levels found in the dried Echinacea purpurea samples were considerably lower with 0.02 mg/kg cadmium, 0.6 mg/kg lead and 0.16 mg/kg arsenic. The relevance of these findings to Echinacea products on the UK market cannot be verified.

88. Another study analysed popular food supplements, including seven Echinacea containing brands, for the presence of heavy metals and microbial contamination (Raman et al., 2004). The supplements, which were purchased from retail stores in Michigan, Illinois and Indiana, were in the form of tablets, capsules or soft gels. The authors determined the daily dose of each heavy metal that would be ingested if the supplement was taken as recommended by the manufacturer. Depending on the Echinacea brand, the daily doses of heavy metals would be: lead 0.034-2.901 μg/day, cadmium 0.004 – 0.967 μg/day, arsenic 0.027 – 0.908 μg/day, chromium 0.125-8.838 μg/day, and thallium 0.002 – 0.383 μg/day. Mercury was not detected in the samples. The authors compared these values to tolerable intake levels at the time of publication and concluded that the supplements do not pose a risk to consumers.

89. Alternaria alternata, Aspergillus spp., Fusarium spp., Phoma spp. and yeasts have been detected in Echinacea herbal supplements at 100-1,000 CFU/g in Echinacea dietary supplements available on the Polish market; 71% of the Echinacea samples (n=7) harboured fungi (Tournas, 2009). Twenty one samples were analysed as part of a study investigating the presence of moulds and their secondary metabolites in Echinacea dietary supplements available on the Polish market (Pilarska et al., 2022). It was found that 12 samples were contaminated with Aspergillus spp., whilst Eurotium and Penicillium spp. were detected in 8 of the samples. Mycotoxin contamination was found in 18 of the samples; zearalenone (18/21), deoxynivalenol (5/21) and T-2 (3/21) were found at the highest frequencies.

Exposure Assessment

90. Echinacea is not used as a food commodity on its own or as an ingredient, but online sources indicate the existence of tea and honey products supplemented with Echinacea and Echinacea extracts that could be consumed as part of the general diet (Appendix B, Table 7). Data from the National Diet and Nutrition Survey (NDNS) (Bates et al., 2014, 2016, 2020; Roberts et al., 2018) on acute herbal and fruit tea consumption and honey among women of childbearing age (16-49 years) may provide an indicator of Echinacea intake from these foods during pregnancy. The acute consumption scenario is considered because Echinacea products are likely to be consumed for a short period of time during an episode of cold/flu during pregnancy. The NDNS does not provide data for pregnant or lactating women, so while data is based on women of childbearing age, this may not be representative of the maternal diet. It is also worth noting that the labelling on some of the Echinacea containing tea products advises pregnant or lactating women to consult a healthcare professional prior to using the product. In contrast, the labelling on Echinacea-containing honey states that it is suitable for pregnant or breastfeeding women. A product comprising lozenges – solid dosage forms formulated with a flavoured or sweetened base that are specifically designed to dissolve or disintegrate slowly in the mouth – is also available. The labelling on this product includes no warnings.

91. The NDNS data indicate that mean acute consumption of herbal and fruit tea by women of childbearing age is 520 mL/person/day; high level (97.5th percentile) is 1,500 mL/person/day (Table 3). The consumption of herbal and fruit tea is used here as a proxy for the consumption of Echinacea tea. Information from Echinacea tea products available suggests preparing the teacup with 227-250 mL hot water and consumption recommendations vary between 2-6 cups per day (Appendix B, Table 7). Based on the Echinacea content of the tea products (Appendix B, Table 7), that would provide 144 - 1005 mg Echinacea per cup of tea, assuming 100% extraction efficiency. Taking the NDNS data for the consumption of herbal and fruit teas and the assumption that a cup of Echinacea tea will be prepared with 250 mL water into consideration, this would equate to the consumption of 6 cups of Echinacea tea per day at the 97.5th percentile by women of childbearing age, an acute exposure of 864 to 6,030 mg of Echinacea per day at the 97.5th percentile.

Table 3. Acute consumption of herbal and fruit tea (as consumed), as a proxy for Echinacea tea consumption (without recipes)

Consumers (n)^ Mean (mL/person/day) 97.5thpercentile (mL/person/day) Mean (mL/kg/ bw/day) 97.5th percentile (mL/kg bw/day)
364 520 1,500 8.0 23

*Rounded to 2 significant figures.

Based on women of childbearing age (16-49 years).

92. The NDNS data on honey consumption (Table 4) suggests that mean acute consumption of honey by women of childbearing age is 15 g/person/day, high level consumption being 48 g/person/day at the 97.5th percentile. Echinacea honey products contain 0.4-2.1 mg Echinacea per 1 g honey (Appendix B, Table 7), corresponding to an estimated acute exposure of 19 to 101 mg of Echinacea per day at the 97.5th percentile from the consumption of Echinacea honey.

Table 4. Acute consumption of honey as a proxy for Echinacea honey consumption (without recipes)

Consumers (n)^ Mean (g/person/day) 97.5th percentile (g/person/day) Mean (g/kg/ bw/day) 97.5th percentile (g/kg bw/day)
293 15 48 0.23 0.75

*Rounded to 2 significant figures.

Based on women of childbearing age (16-49 years).

93. Echinacea supplements available online include solid dosage forms (tablets and capsules; Appendix B, Table 8) and oral liquids (solutions and tinctures; Appendix B, Table 9). Most of these supplements advise consulting a healthcare provider prior to using them during pregnancy/breastfeeding or state that they are not suitable for use during these periods. In addition, some of the supplements recommend short-term use only (5 days to several weeks). For products with herbal blends or unclear directions, the daily Echinacea dose is difficult to determine. Where extracts are specified, tablets/capsules provide 130–700 mg dry herb extract (equivalent to 1,300–7,000 mg herb). Products with dried plant parts contain 400–3,600 mg herb or 500–3,200 mg root. Fewer oral liquid products were found, and some lacked clear composition or usage instructions. Available liquids deliver 500–1,500 mg herb extract or 600–3,000 mg dried herb daily.

94. The Echinacea products for oral use with THR from the MHRA include tablets, capsules, oral solutions, tinctures and oromucosal spray (Appendix B, Table 13). The most common are tablets and capsules containing dry extract of E. purpurea root at daily doses of 143–429 mg (equivalent to 858–3,000 mg root). Preparations from dried pressed juice of E. purpurea herb provide 176–352 mg daily (equivalent to 3.5–9.8 g fresh herb). A comparison between the THR products and the EMA monographs in terms of species used, preparations and doses can be found in Appendix B, Table 14. There is no evidence to suggest that THR products and Echinacea food supplements are taken together during pregnancy, and the assumption is that this is unlikely, especially since the THR products advise against use in pregnancy in their patient information leaflets. In addition, the regulation of THR products is a remit of the MHRA; Echinacea exposure from licensed herbal Echinacea products is therefore not considered in the combined exposure scenarios.

95. Pregnant women may consume Echinacea through various sources, including herbal teas, honey, lozenges, and food supplements such as tablets, capsules, and oral liquids. The FSA’s Exposure Team estimated Echinacea intake during pregnancy under different worst-case scenarios, combining these products. The combined exposure values (Appendix B, Tables 10-12) are based on recommended doses from product labels for food supplements (tablets, capsules, lozenges and oral liquids) and estimated intakes from NDNS consumption data for herbal tea, honey and lozenges. Table 5 presents acute exposure estimates from individual products, while Table 6 shows minimum and maximum combined exposures. Results indicate that combined use of foods and food supplements could reach Echinacea (as dried herb/root) intakes of up to 13,000 mg/day.

Table 5. Estimated minimum and maximum acute exposures to Echinacea (as dried root/herb) from individual Echinacea containing products

Echinacea containing food/food supplement Estimated exposure to Echinacea (mg/day)
Tea 860 – 6,000
Honey 19 - 100
Lozenges 40
Tablets/capsules 400 – 3,600
Oral liquids 600 – 3,000

*Rounded to 2 significant figures.

Table 6. Estimated minimum and maximum acute exposures to Echinacea (as dried root/herb) based on combined consumption of Echinacea products

Number of Echinacea products consumed per day Minimum estimated exposure to Echinacea (mg/day) Maximum estimated exposure to Echinacea (mg/day)
2 60 9,600
3 460 13,000
4-5 1,100 13,000

*Rounded to 2 significant figures.

Risk Characterisation

96. Uncertainties exist regarding the safety of Echinacea supplements consumed during pregnancy and lactation. Three different Echinacea species (E. purpurea, E. pallida and E. angustifolia) are found in supplements, different parts of the plant (root, herb, flower or whole plant) being utilised and different methods of extraction used (powdered plant parts, dry and liquid extracts, pressed and dried pressed juice). The composition of bioactive components varies depending on the preparation and there is currently no consensus on how the Echinacea preparations should be standardised. The impact of differences in composition on the toxicological potential of available products is therefore unknown. In addition, the labelling of some food supplements and food products does not state the Echinacea species, part of plant or preparation type, making comparison between products challenging.

97. Echinacea products are available as foods (Appendix B, Table 7), food supplements (Appendix B, Tables 8-9) and as traditional herbal medicinal products with THR from the MHRA (Appendix B, Table 13). Echinacea food supplements and products with THR share some similarities such as the species (predominantly E. purpurea and E. angustifolia) and use of dosage forms such as capsules, tablets and tinctures. These products are typically single‑herb preparations made from pressed juice or extracts of fresh or dried herb/root. They have defined drug‑extract ratios and both the extract quantity and corresponding herb equivalent are clearly stated.

98. In contrast, Echinacea food supplements are often blended with additional supplements (e.g goldenseal, garlic, multivitamins) and employ mixed use of aerial parts, roots or whole plant or extracts with variable drug‑extract ratios. It is therefore challenging to compare food supplements, which have variable formulations with key information on the species and preparation type and dose sometimes not presented on the label, with THR products, for which established monographs exist and an assessment of the quality and safety has been performed by regulatory agencies.

99. Recommended daily doses of Echinacea food supplement tablets and capsules, where stated on the product label, range from 400 to 3,600 mg (dried herb) and 500 to 3,200 mg (dried root). These doses are comparable to the daily doses of THR products based on dry E. purpurea root extract (143 - 429 mg dry root extract equivalent to 858 – 3,000 mg root).

100. Many, but not all, Echinacea food supplements carry labels warning against the use of the product during pregnancy and lactation. The EMA and the MHRA explicitly advise against the use of Echinacea‑containing medicinal products during pregnancy and lactation due to the absence of high‑quality, guideline‑compliant reproductive and developmental toxicity studies and the limited, insufficient human data available to support safety in these populations. EMA monographs state that, in the absence of robust preclinical evidence and adequately powered human studies, Echinacea medicinal products should not be used during pregnancy or breastfeeding. Likewise, MHRA‑authorised THR products carry mandatory warnings against use in pregnancy and lactation. These recommendations relate specifically to medicinal Echinacea products, for which the composition, dose and quality specifications are defined as part of their product license. In contrast, for many Echinacea food supplements the species, preparation type and dose are not consistently reported, making their composition and exposure levels more uncertain.

101. Echinacea products with THR have a recommended duration of use of no longer than 10 days, in line with the EMA monographs on E. purpurea, E. angustifolia and E. pallida. Some, but not all, commercially available food supplements also advise limited use, typically between 5 days and 2 weeks. Given the indications for Echinacea use and the warnings on most products to avoid prolonged use, Echinacea products are most likely to be consumed in the short term for the treatment and relief of common cold symptoms during pregnancy. Doses of 2,400 - 4,000 mg daily were well tolerated in a 4 month long study with 755 participants (Jawad et al., 2012) and Echinacea has been used in a clinical study for durations up to 6 months at doses of 1,800 mg/day with minimal side effects such as nausea and diarrhoea; however, pregnancy was an explicit exclusion criteria for that trial so it does not provide reassurance regarding the safety of Echinacea consumption during pregancy (Vonau et al., 2001).

102. Exposures to Echinacea estimated by the FSA Exposure assessment team (EAT) range between 400 – 3,600 mg from food supplements (oral liquids, tablets, capsules), 19 - 100 mg from honey and 860 – 6,000 mg from tea products. If a combination of food and food supplement products are taken, exposure levels could reach up to 13,000 mg/day. Echinacea doses used in clinical studies vary between 100 - 4,000 mg/day extract and 6,200 - 10,000 mg/day pressed juice with durations from 5 days to 4 months, E. purpurea and E. angustifolia being the most commonly used.

103. It is important to note that Echinacea preparations are complex mixtures and their assessment presents common challenges associated with mixtures toxicity. These include batch‑to‑batch variability, uncertainties in extraction efficiency (particularly for tea preparations), and variability in the bioavailability of active constituents. A further caveat is that the exposures estimated by the EAT team are based on dried Echinacea root/herb rather than extracts/pressed juice as many of the food supplements and food products either list the Echinacea content as dried plant parts or do not specify the nature of the preparation. A direct comparison is challenging because extracts are generally more concentrated and potent than the dried plant equivalents.

104. There is additional uncertainty surrounding the health risk posed by potential contaminants in Echinacea preparations. Very few studies have looked at the presence of contaminants such as heavy metals, fungi, bacteria and mycotoxins in Echinacea products. Alternaria alternata, Aspergillus spp., Fusarium spp., Phoma spp., yeasts and mycotoxins have been detected in Echinacea herbal supplements available on the Polish market (Tournas, 2009). Whilst cadmium, arsenic and lead have been detected in commercial Echinacea products, their levels were considerably lower than the limits set by WHO and they were not considered to pose a health risk to the public (Filipiak-Szok et al., 2015; Raman et al., 2004).

105. No evidence of genotoxicity has been observed with E. purpurea and E. angustifolia herbal medicinal preparations in bacterial reverse mutation assays, in vitro chromosomal aberration tests or in in vivo micronucleus tests conducted by several OECD guideline-compliant studies. The animal data from studies investigating the acute, subacute and sub-chronic toxicity of Echinacea suggest that overall Echinacea has low toxicity and is well tolerated. Upon reviewing the data from human studies on E. purpurea, EMA (2014) concluded that oral preparations are well tolerated and have an acceptable safety profile with mild, transient and reversible adverse effects, with gastrointestinal disturbances and allergic skin reactions being the most commonly reported adverse effects. However, the EMA does not recommend the use of Echinacea medicinal preparations during pregnancy and lactation due to the lack of guideline-compliant preclinical data on reproductive and developmental toxicity.

106. Case reports and pharmacovigilance data suggested that Echinacea may, rarely, cause severe allergic reactions including anaphylaxis, especially in atopic individuals (Mullins & Heddle, 2002; EMA, 2014). Isolated reports link Echinacea to autoimmune conditions such erythema nodosum, hyperoesinophilia, leucopenia, thrombocytopenia and severe acute cholestatic autoimmune hepatitis. Upon reviewing these case reports, EMA deemed that the causality of adverse events in pharmacovigilance cases concerning autoimmune diseases is inconclusive or not known; association with autoimmune diseases cannot, however, be excluded (EMA, 2014). EMA also stated that, based on the presumption that Echinacea has immunomodulatory properties, it is not recommended in progressive systemic disorders, autoimmune diseases, immunodeficiencies, immunosuppression and diseases of the white blood cell system (EMA, 2014). The COT agreed that individuals with atopic disease or autoimmune disorders will be at higher risk than the general population from exposure to Echinacea products. This should be taken into account for in the risk assessment.

107. Studies have demonstrated that Echinacea and its extracts can inhibit recombinant human cytochrome P450 (CYP) enzymes 3A4, 2E1, 1A2, 2C19 and 2C9 enzymes in vitro to various degrees (Husain et al., 2023; Modarai et al., 2010; Raner et al., 2007; Yale and Glurich, 2005). The total alkylamide content of the Echinacea preparations has been positively associated with its ability to inhibit the CYP enzymes, in particular CYP3A4 (Modarai et al., 2010) and CYP2E1 (Raner et al., 2007). In humans, short-term use (1,600 mg/day E. purpurea for 8 days) inhibited intestinal CYP3A4 and CYP1A2. CYP1A2 inhibition was considered clinically relevant for drugs like theophylline (Gorski, 2004), although no interaction with theophylline has been reported. Longer-term E. purpurea use (1,600 mg/day for 28 days) showed no significant CYP changes (Gurley, 2004). Overall, Echinacea has the potential to interact with medications, but clinical evidence remains limited.

108. The COT agreed there was a lack of high-quality available data on reproductive end points from both animal and human studies. None of the animal studies available on the reproductive and developmental effects of Echinacea conform to OECD guidelines. A potential data gap identified by the Committee was the absence of studies looking at the placenta and the maintenance of pregnancy. This data gap is particularly important given the recommended short-term use of Echinacea which could lead to transient exposure during different parts of the reproductive and developmental cycle. The Committee stated that a risk assessment should also take into account exposure of Echinacea in women of child-bearing potential and during the first trimester (early gestation).

109. Two mouse studies investigated the effects of Echinacea during pregnancy. One focused on spontaneous abortions (Chow et al., 2006) and the other on foetal angiogenesis (Barcz et al., 2007). Chow et al. (2006) reported increased foetal loss in Echinacea treated mice by 12-14 days of gestation and warned against the consumption of Echinacea in the early stages of pregnancy. Barcz et al. (2007) reported a significant decrease in angiogenic factors VEGF and bFGF with the three different Echinacea preparations tested but observed conflicting effects on angiogenic activity: one preparation increased activity, another decreased it, and the third showed no effect. Barcz et al. (2007) concluded that Echinacea may influence foetal angiogenesis and recommended avoiding its use during pregnancy as a precaution.

110. The COT highlighted that small numbers of animals and only one dose of Echinacea were used in both studies. In addition, COT Members were not convinced by the conclusion reached by Chow et al. (2006) stating that Echinacea could lead to miscarriages in early pregnancy because the study had used a DBA mouse strain which has small average litter size and the range/standard deviation for the foetal loss results were not provided.

111. No interventional clinical trials exist on Echinacea use during pregnancy or lactation (EMA, 2014). Limited human data from observational studies (Gallo et al., 2000; Heitmann et al., 2016) and surveys (Cuzzolin et al., 2010; Nordeng et al., 2011) do not indicate adverse maternal or infant effects specifically linked to Echinacea. Both observational studies (Gallo et al., 2000; Heitmann et al., 2016) reported no significant differences in malformations, birth weight, or pregnancy outcomes between exposed and control groups. The COT commented that the sample size in the study by Gallo et al. (2000) would not give sufficient statistical power to detect the birth defects and malformations studied. The COT also highlighted that the limited human studies on the use of Echinacea during pregnancy focussed on observations that can be detected at birth and did not consider any longer-term effects such as epigenetic changes.

112. The human studies suggest that Echinacea is consumed during pregnancy for similar indications as in the general population including the treatment and prevention of cold and flu and respiratory tract infections such as sinusitis, tonsilitis, cough, bronchitis and pneumonia. COT Members highlighted that the Holst et al. (2011) study reporting 4.3% of women using Echinacea during pregnancy was conducted between the months of November and February, which could lead to an overestimation due to increased incidence of cold and flu infections during the winter months. The COT also noted that the transient exposure makes it difficult to determine the percentage of women using Echinacea during the different stages of pregnancy and what the implications of extrapolating from different types of studies are.

113. Overall, the COT agreed that the human studies available lack information about the specific Echinacea species, plant part, type of preparation used, administered dose, the duration of intake and the trimester during which Echinacea was used. It is therefore not possible to directly compare doses used during pregnancy in ‘real life’ situations to exposures estimated by the FSA EAT team. In addition, the COT agreed that the point of departure for Echinacea to be used in risk assessments was difficult to derive due to complexity in terms of preparations, extracts, doses and lack of sufficient, high-quality data to determine clear safety risks. Conclusions

114. Three Echinacea species – E. purpurea, E. angustifolia and E. pallida – have been used medicinally to relieve the symptoms and shorten the duration of cold and flu infections. Echinacea preparations can be made from the dried roots of all three species, the fresh or dried aerial parts and the pressed juice from E. purpurea. Ethanolic extracts are also often used in many Echinacea products. The effects of Echinacea are due to the combination of bioactive metabolites including alkylamides, caffeic acid derivatives and polysaccharides. The composition of these compounds varies across the species, the plant parts, season, growing conditions and extraction methods used.

115. There is evidence from in vitro and in vivo studies that Echinacea preparations can inhibit viral entry and modulate immune responses following infection. Herbal products containing E. purpurea, E. angustifolia and E. pallida have herbal medicinal licenses in EU/EEA member states and THR licenses from the MHRA based on traditional use for the relief of common cold symptoms in adults and children over 12 years of age. Regulatory authorities, including the EMA and MHRA, do not recommend the use of Echinacea containing medicinal products during pregnancy or lactation due to the absence of high‑quality, guideline‑compliant reproductive and developmental toxicity studies and the limited human evidence available. THR licensed Echinacea products in the UK also carry warnings advising against use in these populations. Nevertheless, survey data indicate that up to 10% of pregnant women may use Echinacea for the treatment or prevention of cold and flu symptoms or for immune support.

116. In addition to products with a THR license, foods and food supplements containing Echinacea and its extracts are available over the counter and online. The most common food supplements are tablets and capsules, the majority of which carry a warning against their use in pregnancy/lactation and a recommendation for short term use only. Food products such as tea and honey which contain Echinacea are also available. Products with THR are discussed in this paper where relevant, but the focus of the exposure assessment has been the consumption of Echinacea foods and food supplements.

117. In vitro and in vivo OECD guideline-compliant studies suggest that Echinacea is not genotoxic.

118. In vivo toxicological studies on Echinacea have suggested that it has low toxicity. Clinical studies reported that Echinacea products are well tolerated with minor and reversible side effects including gastrointestinal disturbances and allergic skin reactions. There are isolated case reports of Echinacea causing erythema nodosum, hyperoesinophilia, leucopenia, thrombocytopenia and hepatotoxicity, but causality has not been confirmed. Pharmacovigilance cases and follow up investigation of selected patients also suggest that Echinacea can trigger allergic reactions, as serious in some cases as anaphylaxis, in patients with pre-existing atopic diseases. EMA (2014) recommends Echinacea preparations should be used with caution in patients with asthma or history of atopy. Due to its potential for immune system modulation, Echinacea is also not recommended for people with autoimmune diseases, immunodeficiencies, immunosuppression and diseases of the white blood cell system.

119. There is uncertainty around the potential of Echinacea to interact with prescription medicines during pregnancy. In vitro and in vivo studies demonstrate that Echinacea affects the activity of CYP enzymes leading to inhibition of CYP1A2 and CYP3A4. However, the clinical relevance of these in vitro and in vivo studies is unknown because the number of human studies investigating the interactions of Echinacea with over the counter or prescription medicines is very limited.

120. Contaminants such as heavy metals, fungi, bacteria, mycotoxins and pesticides are sometimes found in herbal preparations. A lack of research creates uncertainty as to the risk posed by potential contaminants in Echinacea preparations pose to pregnant consumers. Studies have reported that cadmium and lead levels detected in Echinacea preparations have been lower than the WHO limits. Nevertheless, the presence of fungal contaminants and mycotoxins detected in some Echinacea products could pose an additional risk during pregnancy.

121. The limited available data from in vitro, in vivo and clinical studies creates uncertainty around the safety of using Echinacea products during pregnancy or lactation. Two studies in mice, one in pigs and two studies in rabbits have addressed the effects of Echinacea supplementation during pregnancy. The two mouse studies highlighted potential increase in foetal loss and altered angiogenesis with Echinacea but the sample sizes were small and some of the results reported on foetal angiogenesis were contradictory. The pig and rabbit studies did not report any significant differences between Echinacea and control groups in relation to birth weight, pregnancy outcomes and frequency of malformations.

122. Human observational studies describing the effects of Echinacea on pregnancy outcomes did not highlight any adverse effects associated with gestational use of Echinacea. These studies rely on self-reported use of Echinacea during pregnancy, and the dose, preparation or duration of use were not specified.

123. The doses used in clinical studies on the efficacy of Echinacea are comparable to the estimated exposures to Echinacea in women of child-bearing age, calculated by the FSA Exposure Assessment Team. Echinacea was well-tolerated in these clinical studies, but they did not include pregnant or lactating women. In addition, an exact comparison between different Echinacea products is challenging because products may contain different combinations of the three medicinally used species, their dried plant parts and extracts. Some food products such as tea and honey often lack information on the exact species, plant parts or extracts used.

124. Overall, the COT concluded that the evidence on the safety of Echinacea during pregnancy is too limited to support a robust risk assessment or the derivation of any health‑based guidance values. Adverse effects are considered unlikely at levels of Echinacea exposure arising from short-term consumption of supplements that are currently available in the UK. However, COT members noted that there are substantial uncertainties in the available safety data, particularly for women thinking of becoming pregnant and pregnant women. The COT does not endorse the use of Echinacea containing supplements by those thinking of becoming pregnant or during pregnancy. These women should avoid taking food supplements unless advised to do so by an appropriately qualified health professional.

COT Statement October 2026

List of Abbreviations

Abbreviation Definition
ADCC Antibody-dependent cellular cytotoxicity
ADR Adverse drug reactions
AIDS Acquired immunodeficiency syndrome
ALT Alanine aminotransferase
ANOVA Analysis of variance
AST Aspartate aminotransferase
bFGF Basic fibroblast growth factor
BMDCs Bone marrow derived dendritic cells
BMI Body mass index
bw Body weight
CFS Chronic fatigue syndrome
CFU Colony forming units
CI Confidence intervals
COX Cyclooxygenase
CYP Cytochrome P450
DER Drug extract ratio
DMSO Dimethyl sulfoxide
DTAI Dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides
ELISA Enzyme-linked immunosorbent assay
EMA European Medicines Agency
GEE Generalised estimating equations
GLP Good laboratory practice
HBGV Health-based guidance values
HCT-116 Human colorectal carcinoma cell line HCT-116
HMR Human Medicines Regulations
HMPC Committee on Herbal Medicinal Products
HPLC High-performance liquid chromatography
HPRT Hypoxanthine phosphoribosyltransferase
HSV Herpes simplex virus
IC₅₀ Half-maximal inhibitory concentration
IgE Immunoglobulin E
IL Interleukin
IFN Interferon
IV Intravenous
5-LOX 5-lipoxygenase
LPS Lipopolysaccharide
MHRA Medicines and Healthcare Products Regulatory Agency
NHANES National Health and Nutrition Examination Survey
NCE Normochromatic erythrocytes
NDNS National Diet and Nutrition Survey
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells
NK cells Natural killer cells
NSAID Non-steroidal anti-inflammatory drugs
OECD Organisation for Economic Co-operation and Development
PARP Poly(ADP-ribose) polymerase
PBMC Peripheral blood mononuclear cells
PCE Polychromatic erythrocytes
P-gp P glycoprotein
RET Reticulocytes
SD rats Sprague-Dawley rats
TGF-β1 Transforming growth factor beta
THR Traditional herbal registration
TNF Tumour necrosis factor
UKTIS UK Teratology Information Service
VEGF Vascular endothelial growth factor
WHO World Health Organization

References

Ahmadi, F., Kariman, K., Mousavi, M., Rengel, Z. (2024). Echinacea: Bioactive Compounds and Agronomy. Plants 13, 1235. https://doi.org/10.3390/plants13091235

Ardjomand-Woelkart, K., Bauer, R. (2015). Review and Assessment of Medicinal Safety Data of Orally Used Echinacea Preparations. Planta Med. 82, 17–31. https://doi.org/10.1055/s-0035-1558096

Ardjomand-Woelkart, K., Kollroser, M., Derendorf, H., Bauer, R., Butterweck, V. (2012). Herb-Drug Interactions: Effects of Echinacea preparations on cytochrome P450 activities in rats. Planta Med. 78, s-0032-1320669. https://doi.org/10.1055/s-0032-1320669

Barcz, E., Sommer, E., Nartowska, J., Balan, B.J., Chorostowska-Wynimko, J., Ewa, Skopińska-Różewska, E. (2007). Influence of Echinacea purpurea intake during pregnancy on fetal growth and tissue angiogenic activity. Folia Histochem Cytobiol. ;45 Suppl 1:S35-9.

Barnes, J., Anderson, L.A., Gibbons, S., Phillipson, J.D. (2010). Echinacea species ( Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J. Pharm. Pharmacol. 57, 929–954. https://doi.org/10.1211/0022357056127

Bates, B.; Lennox, A.; Prentice, A.; Bates, C.; Page, P.; Nicholson, S.; Swan, G. (2014) National Diet and Nutrition Survey Results from Years 1, 2, 3 and 4 (combined) of the Rolling Programme (2008/2009 – 2011/2012) Main heading (publishing.service.gov.uk) Main heading (publishing.service.gov.uk)

Bates, B.; Cox, L.; Nicholson, S.; Page, P.; Prentice, A.; Steer, T.; Swan, G. (2016) National Diet and Nutrition Survey Results from Years 5 and 6 (combined) of the Rolling Programme (2012/2013 – 2013/2014) Main heading (publishing.service.gov.uk)

Bates, B.; Collins, D.; Jones, K.; Page, P.; Roberts, C.; Steer, T.; Swan, G.(2020) National Diet and Nutrition Survey Results from years 9, 10 and 11 (combined) of the Rolling Programme (2016/2017 to 2018/2019) National Diet and Nutrition Survey(publishing.service.gov.uk)

Binns, S.E., Hudson, J., Merali, S., Arnason, J.T. (2002). Antiviral Activity of Characterized Extracts from Echinacea spp. (Heliantheae: Asteraceae) against Herpes simplex Virus (HSV-I). Planta Med. 68, 780–783. https://doi.org/10.1055/s-2002-34397

Blumenthal M, Busse WR, Goldberg A, (1998). The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Boston, MA: American Botanical Council.

Blumenthal, M., Busse, W.R., Bundesinstitut für Arzneimittel und Medizinprodukte (Eds.), (1999). The Complete German Commission E monographs: therapeutic guide to herbal medicines, Reprint. ed. American Botanical Council [u.a.], Austin, Texas.

Buettner, C., Mukamal, K.J., Gardiner, P., Davis, R.B., Phillips, R.S., Mittleman, M.A., (2009). Herbal Supplement Use and Blood Lead Levels of United States Adults. J. Gen. Intern. Med. 24, 1175–1182. https://doi.org/10.1007/s11606-009-1050-5

Burger, R.A., Torres, A.R., Warren, R.P., Caldwell, V.D., Hughes, B.G. (1997). Echinacea-induced cytokine production by human macrophages. Int. J. Immunopharmacol. 19, 371–379. https://doi.org/10.1016/S0192-0561(97)00061-1

Chow, G., Johns, T., Miller, S.C. (2006). Dietary Echinacea purpurea during Murine Pregnancy: Effect on Maternal Hemopoiesis and Fetal Growth. Neonatology 89, 133–138. https://doi.org/10.1159/000088795

Clifford, L.J., Nair, M.G., Rana, J., Dewitt, D.L. (2002). Bioactivity of alkylamides isolated from Echinacea purpurea (L.) Moench. Phytomedicine 9, 249–253. https://doi.org/10.1078/0944-7113-00105

Committee on herbal medicinal products (HMPC) (2007). Community list entry on Echinacea purpurea (L.) Moench, herba recens. Community list entry Echinaceae purpureae (L.) Moench, herba recens (europa.eu)

Currier, N., 2000. Natural killer cells from aging mice treated with extracts from Echinacea purpurea are quantitatively and functionally rejuvenated. Exp. Gerontol. 35, 627–639. https://doi.org/10.1016/S0531-5565(00)00106-6

Currier, N.L., Miller, S.C. (2002). The Effect of Immunization with Killed Tumor Cells, with/Without Feeding of Echinacea purpurea in an Erythroleukemic Mouse Model. J. Altern. Complement. Med. 8, 49–58. https://doi.org/10.1089/107555302753507177

Cuzzolin, L., Francini‐Pesenti, F., Verlato, G., Joppi, M., Baldelli, P., Benoni, G. (2010). Use of herbal products among 392 Italian pregnant women: focus on pregnancy outcome. Pharmacoepidemiol. Drug Saf. 19, 1151–1158. https://doi.org/10.1002/pds.2040

Dabbou, S., Rotolo, L., Kovitvadhi, A., Bergagna, S., Dezzutto, D., Barbero, R., Rubiolo, P., Schiavone, A., De Marco, M., Helal, A.N., Zoccarato, I., Gasco, L. (2016). Rabbit dietary supplementation with pale purple coneflower. 1. Effects on the reproductive performance and immune parameters of does. Animal 10, 1101–1109. https://doi.org/10.1017/S1751731115002979

Dapas, B., Dall’Acqua, S., Bulla, R., Agostinis, C., Perissutti, B., Invernizzi, S., Grassi, G., Voinovich, D. (2014). Immunomodulation mediated by a herbal syrup containing a standardized Echinacea root extract: A pilot study in healthy human subjects on cytokine gene expression. Phytomedicine 21, 1406–1410. https://doi.org/10.1016/j.phymed.2014.04.034

De Fougerolles, A.R., Baines, M.G. (1987). Modulation of the natural killer cell activity in pregnant mice alters the spontaneous abortion rate. J. Reprod. Immunol. 11, 147–153. https://doi.org/10.1016/0165-0378(87)90018-0

Di Lorenzo, C., Ceschi, A., Kupferschmidt, H., Lüde, S., De Souza Nascimento, E., Dos Santos, A., Colombo, F., Frigerio, G., Nørby, K., Plumb, J., Finglas, P., Restani, P. (2015). Adverse effects of plant food supplements and botanical preparations: a systematic review with critical evaluation of causality. Br. J. Clin. Pharmacol. 79, 578–592. https://doi.org/10.1111/bcp.12519

EMA (2012): Assessment report on Echinacea angustifolia DC., radix. EMA/HMPC/688212/2008. Assessment report on Echinacea angustifolia DC., radix (europa.eu)

EMA (2014): Assessment report on Echinacea purpurea (L.) Moench., herba recens. EMA/HMPC/557979/2013. Assessment report on Echinacea purpurea (L.) Moench., herba recens (europa.eu)

EMA (2018): Assessment report on Echinacea pallida (Nutt.) Nutt., radix. EMA/HMPC/737379/2017. Assessment report on Echinacea pallida (Nutt.) Nutt., radix (europa.eu)

EMA monograph (2012): Community herbal monograph on Echinacea angustifolia DC., radix. EMA/HMPC/688216/2008. Community herbal monograph on Echinacea angustifolia DC., radix (europa.eu)

EMA monograph (2014): European Union herbal monograph on Echinacea purpurea (L.) Moench, herba recens. (EMEA/HMPC/104945/2006. European Union herbal monograph on Echinacea purpurea (L.) Moench, herba recens (europa.eu)

EMA monograph (2017): European Union herbal monograph on Echinacea purpurea (L.) Moench, radix. EMA/HMPC/577784/2008. European Union herbal monograph on Echinacea purpurea (L.) Moench, radix (europa.eu)

EMA monograph (2018): European Union herbal monograph on Echinacea pallida (Nutt.) Nutt., radix. (EMEA/HMPC/332350/2008. European Union herbal monograph on Echinacea pallida (Nutt.) Nutt., radix (europa.eu)

Espinosa-Paredes, D.A., Cornejo-Garrido, J., Moreno-Eutimio, M.A., Martínez-Rodríguez, O.P., Jaramillo-Flores, M.E., Ordaz-Pichardo, C. (2021). Echinacea Angustifolia DC Extract Induces Apoptosis and Cell Cycle Arrest and Synergizes with Paclitaxel in the MDA-MB-231 and MCF-7 Human Breast Cancer Cell Lines. Nutr. Cancer 73, 2287–2305. https://doi.org/10.1080/01635581.2020.1817956

European Surveillance of Congenital Anomalies (2014) Guide 1.4, Chapter 3.3. EUROCAT subgroups of congenital anomalies (version 2014; implemented in EDMP December 2014, used for website prevalence tables from December 2014). EUROCAT-Guide-1.4-Section-3.3.pdf

Filipiak-Szok, A., Kurzawa, M., Szłyk, E. (2015). Determination of toxic metals by ICP-MS in Asiatic and European medicinal plants and dietary supplements. J. Trace Elem. Med. Biol. 30, 54–58. https://doi.org/10.1016/j.jtemb.2014.10.008

Fonseca, F.N., Papanicolaou, G., Lin, H., Lau, C.B.S., Kennelly, E.J., Cassileth, B.R., Cunningham-Rundles, S. (2014). Echinacea purpurea (L.) Moench modulates human T-cell cytokine response. Int. Immunopharmacol. 19, 94–102. https://doi.org/10.1016/j.intimp.2013.12.019

Freeman C, Spelman K (2008). A critical evaluation of drug interactions with Echinacea spp. Mol Nutr Food Res. 2008 Jul;52(7):789-98. https://doi.org/10.1002/mnfr.200700113

Fusco, D., Liu, X., Savage, C., Taur, Y., Xiao, W., Kennelly, E., Yuan, J., Cassileth, B., Salvatore, M., Papanicolaou, G.A. (2010). Echinacea purpurea aerial extract alters course of influenza infection in mice. Vaccine 28, 3956–3962. https://doi.org/10.1016/j.vaccine.2010.03.047

Gallo, M., Sarkar, M., Au, W., Pietrzak, K., Comas, B., Smith, M., Jaeger, T.V., Einarson, A., Koren, G. (2000). Pregnancy Outcome Following Gestational Exposure to Echinacea: A Prospective Controlled Study. Arch. Intern. Med. 160, 3141. https://doi.org/10.1001/archinte.160.20.3141

Gan, X.-H., Zhang, L., Heber, D., Bonavida, B. (2003). Mechanism of activation of human peripheral blood NK cells at the single cell level by Echinacea water soluble extracts: recruitment of lymphocyte–target conjugates and killer cells and activation of programming for lysis. Int. Immunopharmacol. 3, 811–824. https://doi.org/10.1016/S1567-5769(02)00298-9

Gendron, R.L., Baines, M.G. (1988). Infiltrating decidual natural killer cells are associated with spontaneous abortion in mice. Cell. Immunol. 113, 261–267. https://doi.org/10.1016/0008-8749(88)90025-1

George, L., Ioannis, E., Radostina, T., Antonios, M. (2006). Severe thrombotic thrombocytopenic purpura (TTP) induced or exacerbated by the immunostimulatory herb Echinacea. Am. J. Hematol. 81, 224–224. https://doi.org/10.1002/ajh.20531

Goel, V., Chang, C., Slama, J.V., Barton, R., Bauer, R., Gahler, R., Basu, T.K. (2002). Echinacea stimulates macrophage function in the lung and spleen of normal rats. J. Nutr. Biochem. 13, 487–492. https://doi.org/10.1055/s-2001-18846

Goey AK, Rosing H, Meijerman I, Sparidans RW, Schellens JH, Beijnen JH.  (2012)The bioanalysis of the major Echinacea purpurea constituents dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides in human plasma using LC-MS/MS. J Chromatogr B, 902:151-156. doi:10.1016/j.jchromb.2012.06.022

Gorski, J. (2004). The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin. Pharmacol. Ther. 75, 89–100. https://doi.org/10.1016/j.clpt.2003.09.013

Gurley, B., Gardner, S., Hubbard, M., Williams, D., Gentry, W., Carrier, J., Khan, I., Edwards, D., Shah, A. (2004). In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin. Pharmacol. Ther. 76, 428–440. https://doi.org/10.1016/j.clpt.2004.07.007

Gurley, B.J., Swain, A., Hubbard, M.A., Williams, D.K., Barone, G., Hartsfield, F., Tong, Y., Carrier, D.J., Cheboyina, S., Battu, S.K. (2008). Clinical assessment of CYP2D6‐mediated herb–drug interactions in humans: Effects of milk thistle, black cohosh, goldenseal, kava kava, St. John’s wort, and Echinacea. Mol. Nutr. Food Res. 52, 755–763. https://doi.org/10.1002/mnfr.200600300

Hall, H.G., Griffiths, D.L., McKenna, L.G. (2011). The use of complementary and alternative medicine by pregnant women: A literature review. Midwifery 27, 817–824. https://doi.org/10.1016/j.midw.2010.08.007

Hansen, T.S., Nilsen, O.G. (2009). Echinacea purpurea and P‐glycoprotein drug transport in Caco‐2 cells. Phytother. Res. 23, 86–91. https://doi.org/10.1002/ptr.2563

Heitmann, K., Havnen, G.C., Holst, L., Nordeng, H. (2016). Pregnancy outcomes after prenatal exposure to Echinacea: the Norwegian Mother and Child Cohort Study. Eur. J. Clin. Pharmacol. 72, 623–630. https://doi.org/10.1007/s00228-016-2021-5

Hellum, B.H., Hu, Z., Nilsen, O.G. (2007). The Induction of CYP1A2, CYP2D6 and CYP3A4 by Six Trade Herbal Products in Cultured Primary Human Hepatocytes. Basic Clin. Pharmacol. Toxicol. 100, 23–30. https://doi.org/10.1111/j.1742-7843.2007.00011.x

Hellum, B.H., Nilsen, O.G. (2007). The in vitro Inhibitory Potential of Trade Herbal Products on Human CYP2D6‐Mediated Metabolism and the Influence of Ethanol. Basic Clin. Pharmacol. Toxicol. 101, 350–358. https://doi.org/10.1111/j.1742-7843.2007.00121.x

HMR 2012: The Human Medicines Regulations 2012. The Human Medicines Regulations 2012 (legislation.gov.uk)

Holst, L., Wright, D., Haavik, S., Nordeng, H. (2011). Safety and efficacy of herbal remedies in obstetrics—review and clinical implications. Midwifery 27, 80–86. https://doi.org/10.1016/j.midw.2009.05.010

Hudson, J., Vimalanathan, S., Kang, L., Amiguet, V.T., Livesey, J., Arnason, J.T. (2005). Characterization of Antiviral Activities in Echinacea Root Preparations. Pharm. Biol. 43, 790–796. https://doi.org/10.1080/13880200500408491

Hudson, J.B. (2012). Applications of the Phytomedicine Echinacea purpurea (Purple Coneflower) in Infectious Diseases. J. Biomed. Biotechnol. 1–16. https://doi.org/10.1155/2012/769896

Huntley, A.L., Thompson Coon, J., Ernst, E. (2005). The Safety of Herbal Medicinal Products Derived from Echinacea Species: A Systematic Review. Drug Saf. 28, 387–400. https://doi.org/10.2165/00002018-200528050-00003

Husain, I., Dale, O.R., Martin, K., Gurley, B.J., Adams, S.J., Avula, B., Chittiboyina, A.G., Khan, I.A., Khan, S.I. (2023). Screening of medicinal plants for possible herb-drug interactions through modulating nuclear receptors, drug-metabolizing enzymes and transporters. J. Ethnopharmacol. 301, 115822. https://doi.org/10.1016/j.jep.2022.115822

Jacobsson, I., Jönsson, A.K., Gerdén, B., Hägg, S. (2009). Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden. Pharmacoepidemiol. Drug Saf. 18, 1039–1047. https://doi.org/10.1002/pds.1818

Jawad, M., Schoop, R., Suter, A., Klein, P., Eccles, R. (2012). Safety and Efficacy Profile of Echinacea purpurea to Prevent Common Cold Episodes: A Randomized, Double-Blind, Placebo-Controlled Trial. Evid. Based Complement. Alternat. Med. 2012, 1–7. https://doi.org/10.1155/2012/841315

Jeong, J.-S., Kim, J.-W., Kim, J.-H., Chung, E.-H., Lee, D.-R., Choi, B.-K., Ko, J.-W., Kim, T.-W. (2024). Oral toxicity and genotoxicity assessment of standardized Echinacea purpurea (L.) extract and the pharmacokinetic profile of its active ingredient chicoric acid. Toxicol. Res. 40, 457–472. https://doi.org/10.1007/s43188-024-00238-z

Kemp, D.E., Franco, K.N. (2002). Possible leukopenia associated with long-term use of Echinacea. J. Am. Board Fam. Pract. 15, 417.

Khaksary Mahabady, M., Ranjbar, R., Arzi, A., Papahn, A.A., Najafzadeh, H. (2006). A comparison study of effects of Echinacea extract and levamisole on phenytoin-induced cleft palate in mice. Regul. Toxicol. Pharmacol. 46, 163–166. https://doi.org/10.1016/j.yrtph.2006.06.005

Kocaman, O., Hulagu, S., Senturk, O. (2008). Echinacea-induced severe acute hepatitis with features of cholestatic autoimmune hepatitis. Eur. J. Intern. Med. 19, 148. https://doi.org/10.1016/j.ejim.2007.04.014

Kovitvadhi, A., Gai, F., Dabbou, S., Ferrocino, I., Rotolo, L., Falzone, M., Vignolini, C., Gennero, M.S., Bergagna, S., Dezzutto, D., Barbero, R., Nebbia, P., Rosati, S., Cocolin, L., Zoccarato, I., Gasco, L. (2016). Rabbit dietary supplementation with pale purple coneflower. 2. Effects on the performances, bacterial community, blood parameters and immunity of growing rabbits. Animal 10, 1110–1117. https://doi.org/10.1017/S1751731115002980

Lee, A.N., Werth, V.P. (2004). Activation of Autoimmunity Following Use of Immunostimulatory Herbal Supplements. Arch. Dermatol. 140. https://doi.org/10.1001/archderm.140.6.723

Lee Soon, S., Crawford, R.I. (2001). Recurrent erythema nodosum associated with Echinacea herbal therapy. J. Am. Acad. Dermatol. 44, 298–299. https://doi.org/10.1067/mjd.2001.112219

Li, Y., Wang, Y., Wu, Y., Wang, B., Chen, X., Xu, Xin, Chen, H., Li, W., Xu, Xiaogang, (2017). Echinacea purpurea extracts promote murine dendritic cell maturation by activation of JNK, p38 MAPK and NF-κB pathways. Dev. Comp. Immunol. 73, 21–26. https://doi.org/10.1016/j.dci.2017.03.002

Maass, N., Bauer, J., Paulicks, B.R., Böhmer, B.M., Roth‐Maier, D.A. (2005). Efficiency of Echinacea purpurea on performance and immune status in pigs. J. Anim. Physiol. Anim. Nutr. 89, 244–252. https://doi.org/10.1111/j.1439-0396.2005.00501.x

Mahajan, D., Sharma, N. R., Kancharla, S., Kolli, P., Tripathy, A., Sharma, A. K., Singh, S., Kumar, S., Mohanty, A. K., & Jena, M. K. (2022). Role of Natural Killer Cells during Pregnancy and Related Complications. Biomolecules, 12(1), 68. https://doi.org/10.3390/biom12010068

Maskatia, Z.K., Baker, K. (2010). Hypereosinophilia Associated with Echinacea Use: South. Med. J. 103, 1173–1174. Hypereosinophilia Associated with Echinacea Use Request PDF

Matthias A, Addison RS, Penman KG, Dickinson RG, Bone KM, Lehmann RP (2005). Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion. Life Sci, 77(16):2018-2029. https://doi.org/10.1016/j.lfs.2005.04.009

Matthias, A., Merika, H., Addison, R., Bone, K., Lehmann, R. (2008). Bioavailability of Echinacea alkylamides in human breast milk. Planta Med. 74, s-0028-1083939. https://doi.org/10.1055/s-0028-1083939

Melchart D, Linde K, Worku F, Sarkady L, Holzmann M, Jurcic K, Wagner H (1995). Results of five randomized studies on the immunomodulatory activity of preparations of Echinacea. J Altern Complement Med. Summer;1(2):145-60. https://doi.org/10.1089/acm.1995.1.145

Melchart, D. (1998). Echinacea Root Extracts for the Prevention of Upper Respiratory Tract Infections: A Double-blind, Placebo-Controlled Randomized Trial. Arch. Fam. Med. 7, 541–545. https://doi.org/10.1001/archfami.7.6.541

Mengs, U., Clare, C.B., Poiley, J.A. (1991). Toxicity of Echinacea purpurea. Acute, subacute and genotoxicity studies. Arzneimittelforschung. 41, 1076–1081.

Merali, S., Binns, S., Paulin-Levasseur, M., Ficker, C., Smith, M., Baum, B., Brovelli, E., Arnason, J.T. (2003). Antifungal and Anti-inflammatory Activity of the Genus Echinacea. Pharm. Biol. 41, 412–420. https://doi.org/10.1076/phbi.41.6.412.17828

Modarai, M., Gertsch, J., Suter, A., Heinrich, M., Kortenkamp, A. (2010). Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content. J. Pharm. Pharmacol. 59, 567–573. https://doi.org/10.1211/jpp.59.4.0012

Mullins, R.J. (1998). Echinacea‐associated anaphylaxis. Med. J. Aust. 168, 170–171. https://doi.org/10.5694/j.1326-5377.1998.tb126773.x

Mullins, R.J., Heddle, R. (2002). Adverse reactions associated with Echinacea: the Australian experience. Ann. Allergy. Asthma. Immunol. 88, 42–51. https://doi.org/10.1016/S1081-1206(10)63591-0

Nordeng, H., Bayne, K., Havnen, G.C., Paulsen, B.S. (2011). Use of herbal drugs during pregnancy among 600 Norwegian women in relation to concurrent use of conventional drugs and pregnancy outcome. Complement. Ther. Clin. Pract. 17, 147–151. https://doi.org/10.1016/j.ctcp.2010.09.002

Ondrizek, R.R., Chan, P.J., Patton, W.C., King, A. (1999). Inhibition of Human Sperm Motility by Specific Herbs Used in Alternative Medicine. J. Assist. Reprod. Genet. 16, 87–91. https://doi.org/10.1023/A:1022568823262

Penzak, S.R., Robertson, S.M., Hunt, J.D., Chairez, C., Malati, C.Y., Alfaro, R.M., Stevenson, J.M., Kovacs, J.A. (2010). Echinacea purpurea Significantly Induces Cytochrome P450 3A Activity but Does Not Alter Lopinavir‐Ritonavir Exposure in Healthy Subjects. Pharmacother. J. Hum. Pharmacol. Drug Ther. 30, 797–805. https://doi.org/10.1592/phco.30.8.797

Perri D, Dugoua JJ, Mills E, Koren G. (2006): Safety and efficacy of Echinacea (Echinacea angustifolia, E. purpurea and E. pallida) during pregnancy and lactation. Can J Clin Pharmacol, 13(3): e262-267.

Pilarska, G., Twarużek, M., Ałtyn, I. (2022). The Presence of Molds and Their Secondary Metabolites in Purple Coneflower-Based Dietary Supplements (Echinacea purpurea (L.) Moench). Toxins 14, 607. https://doi.org/10.3390/toxins14090607

Pleschka, S., Stein, M., Schoop, R., Hudson, J.B. (2009). Anti-viral properties and mode of action of standardized Echinacea purpurea extract against highly pathogenic avian Influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV). Virol. J. 6, 197. https://doi.org/10.1186/1743-422X-6-197

Raman, P., Patino, L.C., Nair, M.G. (2004). Evaluation of Metal and Microbial Contamination in Botanical Supplements. J. Agric. Food Chem. 52, 7822–7827. https://doi.org/10.1021/jf049150+

Raner, G.M., Cornelious, S., Moulick, K., Wang, Y., Mortenson, A., Cech, N.B. (2007). Effects of herbal products and their constituents on human cytochrome P4502E1 activity. Food Chem. Toxicol. 45, 2359–2365. https://doi.org/10.1016/j.fct.2007.06.012

Rininger, J.A., Kickner, S., Chigurupati, P., McLean, A., Franck, Z. (2002). Immunopharmacological activity of Echinacea preparations following simulated digestion on murine macrophages and human peripheral blood mononuclear cells. J. Leukoc. Biol. 68, 503–510. https://doi.org/10.1189/jlb.68.4.503

Roberts, C.; Steer, T.; Maplethorpe, N.; Cox, L.; Meadows, S.; Page, P.; Nicholson, S.; Swan, G. (2018) National Diet and Nutrition Survey Results from Years 7 and 8 (combined) of the Rolling Programme (2014/2015 – 2015/2016) National Diet and Nutrition Survey National Diet and Nutrition Survey (publishing.service.gov.uk)

Schapowal, A., Klein, P., Johnston, S.L. (2015). Echinacea Reduces the Risk of Recurrent Respiratory Tract Infections and Complications: A Meta-Analysis of Randomized Controlled Trials. Adv. Ther. 32, 187–200. https://doi.org/10.1007/s12325-015-0194-4

See, D.M., Broumand, N., Sahl, L., Tilles, J.G. (1997). In vitro effects of Echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients. Immunopharmacology 35, 229–235. https://doi.org/10.1016/S0162-3109(96)00125-7

Sharma, M., Anderson, S.A., Schoop, R., Hudson, J.B. (2009). Induction of multiple pro-inflammatory cytokines by respiratory viruses and reversal by standardized Echinacea, a potent antiviral herbal extract. Antiviral Res. 83, 165–170. https://doi.org/10.1016/j.antiviral.2009.04.009

Spielmann H. The Way Forward in Reproductive/Developmental Toxicity Testing. Alternatives to Laboratory Animals. 2009;37(6):641-656. doi:10.1177/026119290903700609

Svedlund, E., Larsson, M., Hägerkvist, R. (2017). Spontaneously Reported Adverse Reactions for Herbal Medicinal Products and Natural Remedies in Sweden 2007–15: Report from the Medical Products Agency. Drugs - Real World Outcomes 4, 119–125. https://doi.org/10.1007/s40801-017-0104-y

Tournas, V.H. (2009). Microbial contamination of select dietary supplements. J. Food Saf. 29, 430–442. https://doi.org/10.1111/j.1745-4565.2009.00167.x

Tsai, Y.-L., Chiu, C.-C., Yi-Fu Chen, J., Chan, K.-C., Lin, S.-D. (2012a). Cytotoxic effects of Echinacea purpurea flower extracts and chicoric acid on human colon cancer cells through induction of apoptosis. J. Ethnopharmacol. 143, 914–919. https://doi.org/10.1016/j.jep.2012.08.032

Tsai, Y.-L., Chiou, S.-Y., Chan, K.-C., Sung, J.-M., Lin, S.-D. (2012b). Caffeic acid derivatives, total phenols, antioxidant and antimutagenic activities of Echinacea purpurea flower extracts. LWT - Food Sci. Technol. 46, 169–176. https://doi.org/10.1016/j.lwt.2011.09.026

Vimalanathan, S., Kang, L., Amiguet, V.T., Livesey, J., Arnason, J.T., Hudson, J. (2005). Echinacea purpurea. Aerial Parts Contain Multiple Antiviral Compounds. Pharm. Biol. 43, 740–745. https://doi.org/10.1080/13880200500406354

Vonau, B., Chard, S., Mandalia, S., Wilkinson, D., Barton, S.E. (2001). Does the extract of the plant Echinacea purpurea influence the clinical course of recurrent genital herpes? Int. J. STD AIDS 12, 154–158. https://doi.org/10.1258/0956462011916947

Yale, S.H., Glurich, I. (2005). Analysis of the Inhibitory Potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the Metabolic Activity of Cytochrome P450 3A4, 2D6, and 2C9. J. Altern. Complement. Med. 11, 433–439. https://doi.org/10.1089/acm.2005.11.433

Woelkart K, Koidl C, Grisold A, Gangemi JD, Turner RB, Marth E, (2005). Bioavailability and pharmacokinetics of alkamides from the roots of Echinacea angustifolia in humans. J Clin Pharmacol 45(6):683-689. https://doi.org/10.1177/0091270004273493

WHO (1999). Radix echinaceae. In: WHO monographs on selected medicinal plants, Vol. 1, WHO Geneva 1999, Switzerland: 128-135. WHO monographs on selected medicinal plants

Zhai, Z., Liu, Y., Wu, L., Senchina, D.S., Wurtele, E.S., Murphy, P.A., Kohut, M.L., Cunnick, J.E. (2007). Enhancement of Innate and Adaptive Immune Functions by Multiple Echinacea Species. J. Med. Food 10, 423–434. https://doi.org/10.1089/jmf.2006.257

Appendix A

Search methodology

1. The following electronic databases were searched for relevant articles published between 2014 and 2024: LitFetch (which includes material from PubMed, Scopus, Ebsco (Food Science Source) and Springer), Google and Google Scholar. The searches were conducted on various dates between 13th May 2024 and 24th May 2024.

2. The search terms used included ‘echinacea’ AND: (‘pregnan’ OR ‘maternal’ OR ‘reproduction’ OR ‘gestation’ OR ‘lactation’ OR ‘preconception’ OR ‘development’ OR ‘tox*’ OR ‘safety’ OR ‘uses’ OR ‘consumption’ OR ‘indication’ OR ‘interaction’).

3. The references from extracted papers were searched for citations not captured in the literature search. Only articles published in English were included, due to the linguistic abilities of the reviewer.

4. The UKTIS was also asked for information on any enquiries relating to maternal echinacea use and any reports of adverse effects in pregnant women or their newborn infants received from 1983 to June 2024. This included information relating to the type, dosage, duration, and timing of echinacea taken and any pregnancy outcomes captured through follow-up.

Appendix B

Table 7. Food products containing Echinacea

Product name Type Echinacea species and plant part Composition Directions for use Daily dose of Echinacea (mg) Additional information/ warnings
Pukka Herbs Elderberry and Echinacea Organic Herbal Tea Tea bags Echinacea (species not specified) herb Ginger root, liquorice root, Echinacea herb (11%), beetroot, aniseed, rosehip, peppermint leaf, orange peel, elderflower (5%), elderberry (4%), hibiscus, orange essential oil flavour, blackcurrant flavour. Not specified Not specified Not specified
Yogi Tea Echinacea Special Formula Tea bags Not specified Cinnamon, Echinacea, ginger, fennel, rooibos, roasted chicory, carob, cardamom, basil, burdock root, black pepper, turmeric root, astragalus, vanilla beans. Pour 250 ml of freshly boiled water over the teabag. Allow to infuse for 5 to 6 minutes - or longer for a stronger flavour. Not specified Not specified
Yogi Tea, Echinacea Immune Support, Caffeine Free, 16 Tea Bags, 0.85 oz (24 g) Tea bags Echinacea purpurea Plant part not specified Each tea bag contains: 144 mg Echinacea purpurea, 47 mg Echinacea purpurea extract, 1,245 mg herb blend (rose hips, dried acerola juice, basil, cinnamon, ginger, cardamom, elderberries, black pepper, moringa, hibiscus, cocoa shells, liquorice, fennel) Bring water to boiling and steep 7 minutes. For a stronger tea, use 2 tea bags. Drink 3-4 cups daily. 432 - 1,152 mg Echinacea purpurea and 141 - 376 mg Echinacea purpurea extract Consult your healthcare provider prior to use if you are pregnant or nursing, taking any medication or if you have a medical condition.
Traditional Medicinals, Organic Echinacea Plus, Elderberry, Caffeine Free, 16 Wrapped Tea Bags, 0.85 oz (24 g) Tea bags Echinacea purpurea herb Each tea bag contains: 1005 mg Echinacea purpurea herb, 127.5 mg European elder flower, 1,245 mg herb blend (ginger rhizome, chamomile flower, yarrow flower, peppermint leaf, Echinacea purpurea root dry extract (2-8:1), European elder fruit dry concentrate) Pour 8 oz (~227 mL) freshly boiled water over 1 tea bag. Cover & Steep for 10-15 min. Enjoy 5-6 cups throughout the day. 5,025 - 6,030 mg Echinacea purpurea herb Do not use if you are pregnant or breastfeeding unless directed otherwise by your healthcare practitioner. Not recommended for use with children under 12 years of age.
Traditional Medicinals, Organic Immune Zoom®, Lemon Ginger Echinacea, Caffeine Free, 16 Wrapped Tea Bags, 1.13 oz (32 g) Tea bags Echinacea purpurea root 2,000 mg herb blend (ginger rhizome, Echinacea purpurea herb, lemon myrtle leaf (Backhousia citriodora), lemon peel, liquorice root, peppermint leaf, Echinacea purpurea root dry extract (2-8:1), cardamom seed, Organic liquorice root dry extract (6:1). Pour 8 oz (~227 mL) freshly boiled water over 1 tea bag. Cover & Steep for 10-15 min. Enjoy 2 cups throughout the day. Not specified Consult your healthcare practitioner prior to use if you are pregnant or breastfeeding; or if you have an autoimmune or other immune system disorder, or if you are taking immunosuppressants; or if you have liver or gallbladder disease. Not recommended for use with children under 12 years of age.
Superblends Defence 20 Tea Bags Tea bags Echinacea (species not specified) root Green tea (26%), Ginger root (15%), White hibiscus, Cinnamon bark, Natural lemon Flavouring with other Natural Flavourings (10%), Echinacea root (9%), Lemon peel (5%), Natural flavouring, Natural lime flavouring (4%), vitamin C (2%). At least 1 cup a day. Not specified Not specified
Frontier Co-op, Organic Cut & Sifted Echinacea Angustifolia Root Loose herb for tea Echinacea angustifolia root Half a teaspoon contains 1.1 g cut root. To prepare as tea, pour 8 oz. (~227 mL) boiling water over 1/2 teaspoon of root. Cover and steep 20-30 minutes, strain and serve immediately. Not specified If pregnant, nursing, suffering from any medical condition, or taking medication, consult a healthcare practitioner before use.
Frontier Co-op, Organic Elderberry Echinacea Wellness Tea, 16 oz Loose herb for tea Echinacea purpurea herb and root Elderberry, Echinacea purpurea herb, peppermint, yarrow, ginger, chamomile flower, Echinacea purpurea root. Pour 8 oz. (227 mL) boiling water over 1 tablespoon of tea. Cover and steep 10-15 minutes, strain and serve immediately. Not specified If pregnant, nursing, suffering from any medical condition, or taking medication, consult a healthcare practitioner before use.
Frontier Co-op, Cut & Sifted Echinacea Purpurea Herb Loose herb for tea Echinacea purpurea herb One teaspoon contains 820 mg Echinacea purpurea cut herb. To prepare as a tea, pour 8 oz. (~227 mL) boiling water over 1 teaspoon of herb. Cover and steep 3-5 minutes, strain and serve immediately. Not specified Not specified
Lemon & Ginger Vitamin Honey Honey Not specified 1 teaspoon (7g) contains: 15 mg Echinacea, 3 mcg vitamin D3, 10mg vitamin C, 0.4 mcg vitamin B6, 0.4 mcg vitamin B12. 2 teaspoons into warm water Not specified This product is suitable for pregnant or breastfeeding women, however we’d always recommend that you consult with a health professional if you are unsure before making a purchase.
Orange Vitamin Honey Honey Not specified 1 teaspoon contains: 15 mg Echinacea, 3 mcg vitamin D3, 10mg vitamin C, 0.4 mcg vitamin B6, 0.4 mcg vitamin B12. 2 teaspoons into warm water Not specified This product is suitable for pregnant or breastfeeding women, however we’d always recommend that you consult with a health professional if you are unsure before making a purchase.
Wedderspoon Natural Manuka Honey and Ginger with Echinacea Drops (20 Drops per box) Honey Not specified Organic cane sugar, organic manuka honey (15.5%), organic brown rice syrup, ground ginger (0.6%), Echinacea (0.04%). Not specified Not specified Not specified
A.Vogel Echinacea Lozenges Extract of Freshly Harvested Echinacea  Blend of Other Herbs Suitable for Vegetarians 30g Lozenges Echinacea purpurea herb and root extract Each lozenge (2.2 g) contains: Glucose syrup, raw cane sugar, honey, herb extracts, fresh Echinacea purpurea extract (0.62%), natural flavours, caramel colour, menthol, peppermint essential oil, citric acid. As required Not specified Not specified
Honey Lemon Echinacea Soothe & Clear Drops 75g (Ricola) Lozenges Echinacea (species not specified) dry pressed juice Sugar, glucose syrup, Fair Trade honey (5.1%), extract (0.5%) of Ricola’s herb mixture, vitamin C, lemon juice concentrate, acid (citric acid, malic acid), natural flavourings, natural Echinacea aroma (Echinacea dry pressed juice), mint oil, peppermint oil, menthol. As required Not specified Not specified
Swanson, Zinc & C with Elderberry & Echinacea, Orange & Lemon, 60 Lozenges Lozenges Echinacea purpurea herb (aerial parts) powder Each lozenge contains: 100 mg vitamin C, 25 mg zinc, 20 mg Echinacea purpurea powder, 20 mg elderberry extract. As a dietary supplement, dissolve one lozenge in the mouth two times per day. 40 mg Echinacea purpurea powdered herb Not specified

Table 8. Echinacea food supplements (solid dosage forms)

Product name Dosage form Echinacea species and plant part Composition Directions for use Daily dose Echinacea (mg) Additional information
NOW Foods Echinacea 400 mg 100 Veg Capsules Capsules Echinacea purpurea root 400 mg root. Take 2 capsules 1 to 4 times daily as needed. Continuous high level consumption of this product for more than 2 weeks of each month is not recommended. 800 - 3,200 mg root For adults only. Consult physician if pregnant/nursing, taking medication, or have a medical condition.
Grape Tree Echinacea Root 500mg Tablets Echinacea (species not specified) root 500 mg root 1 tablet daily. 500 mg root Linked to many health benefits including reduced inflammation, improved immunity and lower blood sugar levels.
Swanson Echinacea, 400mg herbal supplement Capsules Echinacea purpurea herb (aerial parts) 400 mg herb. 1 capsule up to 3 times per day. Limit use to eight consecutive weeks. Use periodically for a few weeks at a time (for maintenance purposes). 400-1,200 mg herb For adults only. Do not take this product if you are pregnant or nursing. Consult your healthcare provider before using this or any product if you are taking medication or have a medical condition, especially an autoimmune condition.
Echinacea, 1300 mg (per serving), 180 Vegetarian Capsules Capsules Echinacea purpurea herb (aerial parts) 65 mg herb extract (DER 10:1) equivalent to 650 mg herb. Take 2 vegetarian capsules per day preferably with a meal. 130 mg herb extract equivalent to 1,300 mg herb If you are pregnant, nursing, taking any medications or have any medical conditions, consult your doctor before use.
Life Extension, Echinacea Elite, 60 Vegetarian Capsules Capsules Echinacea purpurea herb and Echinacea angustifolia root Echinacea purpurea (aerial parts) extract 125 mg [standardised to 4% phenolic compounds]. Echinacea angustifolia (root) extract 125 mg [standardised to 4% echinacosides] Take 1 capsule twice daily 250 mg Echinacea purpurea (aerial parts) extract and 250 mg Echinacea angustifolia (root) extract Consult with your physician if you are undergoing treatment for a medical condition or if you are pregnant or lactating.
Specialist Herbal Supplies (SHS) Echinacea Capsules Capsules Echinacea angustifolia 325 mg. Preparation not specified. 1 capsule, 3 times a day, taken with food or a drink. If desired, up to four times this amount can safely be taken. 975-1,300 mg Echinacea angustifolia If you are pregnant, breast-feeding, have a medical condition or are under medical supervision, please consult a doctor before use.
Nuke Nutrition Echinacea Tablets High Strength x180 - Immune Support Echinacea Herbal Supplements Tablets Echinacea. Species and part of plant not specified. 200 mg extract (DER 10:1) equivalent to 2,000 mg Echinacea. Take 1 tablet with your first meal of the day. 200 mg extract equivalent to 2,000 mg Echinacea Consult your physician if you are taking medication or are under medical supervision or if you are pregnant and breastfeeding.
Echinacea Extract Capsules 3500mg (High Strength) Echinacea purpurea Capsules Echinacea purpurea. Plant part not specified. 350 mg extract (DER 10:1) equivalent to 3,500 mg Echinacea pupurea Take 1 capsule per day with water. 350 mg extract equivalent to 3,500 mg Echinacea purpurea Not specified
Nature’s Way, Echinacea Goldenseal, 450 mg, 100 Vegan Capsules Capsules Echinacea purpurea herb (aerial parts) and Echinacea angustifolia root 450 mg Echinacea 7 Herb Blend: Echinacea purpurea (stem, leaf, flower), Goldenseal (root), Echinacea angustifolia (root), Burdock (root), Gentian (root), Cayenne Pepper (fruit), Wood Betony (stem, leaf, flower) Take 2 capsules twice daily, preferably with food. 1,800 mg Echinacea 7 herb blend. Exact dose of Echinacea cannot be determined. Do not use if you are pregnant, nursing, have stomach or duodenal ulcers, stomach irritation or inflammation. Not recommended for individuals with autoimmune conditions. If you have diabetes, or are taking any medications, consult a healthcare professional before use.
Nature’s Way, Echinacea Purpurea Herb, 1,200 mg, 180 Vegan Capsules (400 mg per Capsule) Capsules Echinacea purpurea herb (aerial parts) 400 mg herb Adults take 3 capsules three times daily, preferably with food. Only take this supplement if they are suffering severe illness to stimulate the immune system and to not take for longer than 5 days. 3,600 mg herb If pregnant, nursing, or taking any medications, consult a healthcare professional before use.
California Gold Nutrition, EuroHerbs, Echinacea Herb Extract, Euromed Quality, 80 mg, 180 Veggie Capsules Capsules Echinacea purpurea herb (aerial parts) 80 mg Echinacea purpurea (aerial parts) extract (DER 5:1) equivalent to 400 mg dried herb. Take 1 capsule daily, with food. 80 mg extract equivalent to 400 mg dried herb. Pregnant or lactating women should consult with a physician, pharmacist, naturopath or other qualified healthcare professional prior to taking dietary supplements.
21st Century, Echinacea Complex, 250 mg, 60 Vegetarian Capsules (125 mg per Capsule) Capsules Echinacea purpurea herb and Echinacea angustifolia root 125 mg Echinacea blend (Echinacea purpurea herb extract and Echinacea angustifolia root powder) Adults take two (2) capsules daily with any meal or as directed by a healthcare provider. 250 mg Echinacea blend (Echinacea purpurea herb extract & Echinacea angustifolia root powder) Consult a healthcare provider prior to use if pregnant, nursing, on medications, have a medical condition or are planning a medical procedure.
Sundown Naturals, Whole Herb Echinacea, 400 mg, capsules Capsules Echinacea purpurea herb (aerial parts) 400 mg Echinacea purpurea herb Take (1) capsule seven times daily, preferably with meals. Capsules may be opened and prepared as a tea. 2,800 mg herb If you are pregnant, nursing, taking any medications or have any medical condition, consult your doctor before.
Gaia Herbs, Echinacea Goldenseal, 60 Vegan Liquid Phyto-Caps Capsules Echinacea purpurea root, aerial parts and seed and Echinacea angustifolia root 800 mg Proprietary Extract Blend: Echinacea purpurea root, Goldenseal (Hydrastis canadensis) root, Echinacea angustifolia root, Echinacea purpurea seed, St. John’s Wort (Hypericum perforatum) aerial parts, Echinacea purpurea aerial parts Adults take 2 capsules 3 times daily between meals. 4,800 mg Proprietary Extract Blend. Exact dose of Echinacea cannot be determined. Not for use during pregnancy or lactation.
Specialist Herbal Supplies (Shs) Echinacea Compound Capsules Echinacea angustifolia Echinacea angustifolia 92mg, Garlic 92mg, Myrrh 92mg, Wild Indigo 46mg. Echinacea preparation not specified. 1 capsule, 3 times a day, taken with food or a drink. 276 mg Echinacea angustifolia Do not take alongside blood thinning drugs such as warfarin. Not to be used in pregnancy and breastfeeding or for children under 12 years old.

Table 9. Echinacea food supplements (oral liquids)

Product name Dosage form Echinacea species and plant part Composition Directions for use Daily dose Echinacea (mg) Additional information
Nature’s Way, Echinacea, 500 mg, 1 fl oz (30 mL) Oral solution Echinacea purpurea herb (aerial parts) 250 mg herb extract per 1 mL Adults: Take 2 mL 3 times daily. Children ages 6-12 years of age: Take 1 mL 3 times daily. Intensive: Take 2 mL every 2 hours for first 48 hours. Then take 2 ml 3 times daily for next 8-9 days. May be added to foods/drinks. Adults: 500-1,500 mg herb extract. Children: 250-750 mg herb extract. If pregnant, nursing, or taking any medications, consult a healthcare professional before use. Not recommended for individuals with auto-immune conditions.
Echinacea Single Herbal Tincture 150mL Tincture Echinacea (species not specified) Dried herb to liquid ratio W/V 1:5 or fresh herb to liquid ratio W/V 1:3 Dosage is normally between 1mL and 5 mL added to a little water up to three times a day. 3 - 15 mL herb extract daily equivalent to 600 -3,000 mg dried herb or 1,000 - 5,000 mg fresh herb. Not specified
Baldwins Echinacea (angustifolia) Herbal Tincture Tincture Echinacea angustifolia Herb:Liquid 1:3 No guidance No guidance Not specified
Napiers the Herbalists Napiers Organic Echinacea Drops Oral drops Echinacea purpurea herb (aerial parts) Not stated Take 15-20 drops 2-3 times a day. 15 drops = 0.5 mL. 30 - 60 drops daily. Equivalent to 1-2 mL solution. Not suitable for children under 12 years. Do not take if pregnant or breastfeeding.
100% Organic Echinacea Tincture Viridian 50ml Tincture Echinacea purpurea whole plant 1 mL = 480 mg whole fresh plant Take 15 – 30 drops, 2-3 times daily in a little fruit juice or water. 15 drops = 0.5 mL. 31 - 60 drops daily. Equivalent to 1-2 mL solution or 480 - 960 mg fresh plant. Not to be used during pregnancy or lactation unless recommended by a healthcare practitioner.
NOW Foods, Echinacea Extract, 2 fl oz (59 ml) Oral solution Echinacea angustifolia and Echinacea purpurea root Root extract. 1.6 mL per 2 droppersfuls Take 1 to 2 droppersful in tea or water 1 to 3 times daily as needed.  Continuous high-level consumption of this product for more than 2 weeks of each month is not recommended. 0.8 - 4.8 mL Not recommended for pregnant or nursing women.
Cytoplan Organic Echinacea Oral solution Echinacea angustifolia 1:3 extract Take 20 drops mixed into water or liquid of choice 2-3 times daily. 20 drops = 2mL. 40-60 drops daily. Equivalent to 4-6 mL extract daily. Not suitable for children under 12 years of age. Not suitable for use whilst pregnant or breastfeeding.

Table 10. Combined acute exposure scenarios for the consumption 4-5 products of Echinacea (as dried root/herb) during pregnancy

Tea: Estimated exposure to Echinacea (mg/day) Honey: Estimated exposure to Echinacea (mg/day) Lozenges: Estimated exposure to Echinacea (mg/day) Tablets/capsules: Estimated exposure to Echinacea (mg/day) Oral liquids: Estimated exposure to Echinacea (mg/day) Total consumed per day: Estimated exposure to Echinacea (mg/day)
860 - 6,000 19 - 100 40 400 - 3,600 600 - 3,000 1,900 - 13,000
N/A 19 - 100 40 400 - 3,600 600 - 3,000 1,100 - 6,700
860 - 6,000 N/A 40 400 - 3,600 600 - 3,000 1,900 -13,000
860 - 6,000 19 - 100 N/A 400 - 3,600 600 - 3,000 1,900 - 13,000
860 - 6,000 19 - 100 40 N/A 600 - 3,000 1,500 - 9,100
860 - 6,000 19 - 100 40 400 - 3,600 N/A 1,300 - 9,700

*Rounded to 2 significant figures.

Table 11. Combined acute exposure scenarios for the consumption of 3 products of Echinacea (as dried root/herb) during pregnancy

Tea: Estimated exposure to Echinacea (mg/day) Honey: Estimated exposure to Echinacea (mg/day) Lozenges: Estimated exposure to Echinacea (mg/day) Tablets/capsules: Estimated exposure to Echinacea (mg/day) Oral liquids: Estimated exposure to Echinacea (mg/day) Total consumed per day: Estimated exposure to Echinacea (mg/day)
860 - 6,000 19 - 100 40 N/A N/A 920 - 6,100
860 - 6,000 19 - 100 N/A 400 - 3,600 N/A 1,300 - 9,700
860 - 6,000 19 - 100 N/A N/A 600 - 3,000 1,500 - 9,100
860 - 6,000 N/A N/A 400 - 3,600 600 - 3,000 1,900 - 13,000
860 - 6,000 N/A 40 400 - 3,600 N/A 1,300 - 9,600
860 - 6,000 N/A 40 N/A 600 - 3,000 1,500 - 9,000
N/A N/A 40 400 - 3,600 600 - 3,000 1,000 - 6,700
N/A 19 - 100 N/A 400 - 3,600 600 - 3,000 1,000 - 6,700
N/A 19 - 100 40 400 - 3,600 N/A 460 - 3,700
N/A 19 - 100 40 N/A 600 - 3,000 660 - 3,100

*Rounded to 2 significant figures.

Table 12. Combined acute exposure scenarios for the consumption of 2 products of Echinacea (as dried root/herb) during pregnancy

Tea: Estimated exposure to Echinacea (mg/day) Honey: Estimated exposure to Echinacea (mg/day) Lozenges: Estimated exposure to Echinacea (mg/day) Tablets/capsules: Estimated exposure to Echinacea (mg/day) Oral liquids: Estimated exposure to Echinacea (mg/day) Total consumed per day: Estimated exposure to Echinacea (mg/day)
860 - 6,000 19 - 100 N/A N/A N/A 900 - 6,100
860 - 6,000 N/A 40 N/A N/A 900 - 6,000
860 - 6,000 N/A N/A 400 - 3,600 N/A 1,300 - 9,600
860 - 6,000 N/A N/A N/A 600 - 3,000 1,500 - 9,600
N/A 19 - 100 40 N/A N/A 60 - 140
N/A 19 - 100 N/A 400 – 3,600 N/A 420 - 3,700
N/A 19 - 100 N/A N/A 600 - 3,000 620 - 3,100
N/A N/A 40 400 - 3,600 N/A 440 - 3,600
N/A N/A 40 N/A 600 - 3,000 640 - 3,000
N/A N/A N/A 400 - 3,600 600 - 3,000 1,000 - 6,600

*Rounded to 2 significant figures.

Table 13. Echinacea products (oral dosage forms) with THR in the UK

Product name Dosage form Echinacea species and plant part Composition Directions for use Daily dose Echinacea (mg)
Echinaflu Soft Capsules Capsules Echinacea purpurea (L.) Moench herb 176 mg of dried pressed juice from fresh flowering herb equivalent to 3.5-4.9 g of fresh herb (DER 20-28:1). 1-2 capsules daily for no longer than 10 days. 176 - 352 mg dried pressed juice equivalent to 3.5 - 9.8 g fresh herb.
Echinacea Cold and Flu Capsules Capsules Echinacea purpurea (L.) Moench) root 140 mg dry extract from root equivalent to 838 - 1117 mg root (DER 6-8:1). 1 capsule twice a day. 280 mg dry root extract equivalent to 1,676- 2,234 mg root.
Ekinalife Capsules Echinacea pallida (Nutt.) Nutt. root and  Echinacea purpurea (L.) Moench root 200mg of Echinacea pallida. Nutt. and 200mg of Echinacea purpurea (L.) Moench powedered root. 1 capsule twice a day for no longer than 10 days. 400 mg E. pallida powdered root and 400 mg E. purpurea powdered root. Total of 1,600 mg powdered root.
Solgar Echinacea Cold and Flu Capsules Capsules Echinacea purpurea (L.) Moench root 140 mg dry extract from root equivalent to 838 - 1117 mg root (DER 6-8:1). 1 capsule twice a day for no longer than 10 days. 280 mg dry root extract equivalent to 1,676- 2,234 mg root.
Phytocold Capsules Echinacea purpurea (L.) Moench root 250 mg powdered root. 1-2 capsules three times a day for no longer than 10 days. 750 - 1,500 mg powdered root.
Echinaflu Effervescent Tablets Effervescent Tablets Echinacea purpurea (L.) Moench herb 176 mg of dried pressed juice from fresh flowering herb equivalent to 3.5-4.9 g of fresh herb (DER 20-28:1). 1-2 tablets daily for no longer than 10 days. 176 - 352 mg dried pressed juice equivalent to 3.5 - 9.8 g fresh herb.
Echineeze Tablets Echinacea purpurea (L.) Moench root 70 mg dry extract from root equivalent to 460 – 530 mg root (DER 6.5-7.5:1). 1 tablet 3 times a day for no longer than 10 days. 210 mg dry root extract equivalent to 1,380 - 1,590 mg root.
Echinaforce Forte Cold & Flu Tablets Tablets Echinacea purpurea (L.) Moench herb and root 1,140 mg dry extract from fresh herb (DER 1:12) and 60 mg (DER 1:11) dry extract from fresh root. 1 tablet two to three times a day for no longer than 10 days. 2,280 - 3,420 mg dry herb extract and 120-180 mg dry root extract.
Herbal Cold And Flu Relief Tablets Tablets Echinacea purpurea (L.) Moench root 71.5 mg dry extract from root equivalent to 429 - 500 mg root (DER 6-7:1). 1-2 tablets twice daily for no longer than 10 days. 143-286 mg dry root extract equivalent to 858 - 2,000 mg root.
High Strength Herbal Cold And Flu Relief Tablets Tablets Echinacea purpurea (L.) Moench root 143 mg dry extract from root equivalent to 858 - 1000 mg root (DER 6-7:1). 1 tablet three times a day for no longer than 10 days. 429 mg dry root extract equivalent to 2,574 - 3,000 mg root.
Echinacea Skin Care Tablets Tablets Echinacea purpurea (L.) Moench root 71.5 mg dry extract from root equivalent to 429 - 500 mg root (DER 6-7:1). 1-2 tablets three times a day for no longer than 10 days. 143-286 mg dry root extract equivalent to 858 - 2,000 mg root.
Herbal Classics Echinacea Cold Relief Film-Coated Tablets Tablets Echinacea purpurea (L.) Moench root 40 mg dry extract from root equivalent to 260 mg root (DER 6.5:1). 2-3 tablets three times a day. 240-360 mg dry root extract equivalent to 1,560 -2,340 mg root.
HRI Cold And Flu Echinacea Tablets Tablets Echinacea purpurea (L.) Moench root 56 mg dry extract from root equivalent to 338 - 450 mg root (DER 6-8:1). 1-2 tablets twice daily. 112-224 mg dry root extract equivalent to 676-1,800 mg root.
Echinapret Coated Tablets Tablets Echinacea purpurea (L.) Moench herb 175 mg of dried pressed juice from fresh flowering herb equivalent to 6.7 - 9.8 g fresh herb (DER 38 - 56:1). 1 tablet three times a day for no longer than 10 days. 525 mg dried pressed juice equivalent to 18.4 - 29.4 mg fresh herb.
Thompson and Capper Echinacea Cold-n-Flu-Eze Tablets Echinacea purpurea (L.) Moench root 105 mg dry extract from root equivalent to 630 - 840 mg root (DER 6-8:1). 1 tablet twice a day for no longer than 10 days. 210 mg dry root extract equivalent to 1,260 -1,680 mg root.
Fuerte Tablets Tablets Wild indigo root (Baptisia tinctoria (L.) R.Br.), Echinacea purpurea root (Echinacea purpurea (L.) Moench), Echinacea pallida root (Echinacea pallida (Nutt.) Nutt.), White cedar tips and leaves (Thuja occidentalis L.) 3.2 mg dry root extract (DER 4-9:1) from Wild indigo root, E. purpurea root, E. pallida root and Wild cedar tips and leaves (4.92:1.85:1.85:1) 5 tablets three times a day for no longer than 10 days. 9.2 mg E. pallida and 9.2 mg E. purpurea dry root extract. Total 18.4 mg dry root extract equivalent to 73.6-165.6 mg root.
Healthsense Echinashield Cold and Flu Tablets Tablets Echinacea purpurea (L.) Moench root 70 mg dry extract from root equivalent to 420 - 560 mg root (DER 6-8:1). 1 tablet three times a day for no longer than 10 days. 210 mg dry root extract equivalent to 1,260 -1,680 mg root.
Lamberts Echinacea Cold &  Flu relief tablets Nature’s Best Echinacea Cold & Flu Relief tablets Tablets Echinacea purpurea (L.) Moench root 105 mg dry extract from root equivalent to 630 - 840 mg root (DER 6-8:1). 1 tablet twice a day for no longer than 10 days. 210 mg dry root extract equivalent to 1,260 -1,680 mg root.
Vitabiotics Echinacea Tablets Tablets Echinacea purpurea (L.) Moench root 200 mg dry extract from root equivalent to 1200 - 1600 mg root (DER 6-8:1). 1 tablet twice a day for no longer than 10 days. 400 mg dry root extract equivalent to 2,400 -3,200 mg root.
Potter’s Skin Clear Tablets Tablets Echinacea angustifolia (D.C) root 110 mg dry extract from root equivalent to 500 mg root (DER 4.5:1). 2 tablets three times a day for no longer than 10 days. 660 mg dry root extract equivalent to 2,970 mg root.
EKINACLEAR Tablets Echinacea purpurea (L.) Moench root 50 mg dry extract from root equivalent to 300 - 400 mg root (DER 6-8:1). 1-2 tablets three times a day for no longer than 10 days. 150-300 mg dry root extract equivalent to 900-2,400 mg root.
Lifeplan Echinacea Cold and Flu Relief Tablets Tablets Echinacea purpurea (L.) Moench root 140 mg dry extract from root equivalent to 840 - 1120 mg root (DER 6-8:1). 1 tablet twice a day for no longer than 10 days. 280 mg dry root extract equivalent to 1,680-2,400 mg root.
Echinaforce Chewable Cold & Flu Tablets Chewable tablets Echinacea purpurea (L.) Moench herb and root 380 mg dry extract from fresh herb (DER 1:12) and 20 mg dry extract (DER 1:11) from fresh root. 2 tablets two to three times a day for no longer than 10 days. 1,520 - 2,280 mg dry herb extract and 80-120 mg dry root extract.
Herbal Cold And Flu Sachets Sachets Echinacea purpurea (L.) Moench root 71.5 mg dry extract from root equivalent to 429 - 500 mg root (DER 6-7:1). 1 sachet three times a day for no longer than 10 days. 214.5 mg dry root extract equivalent to 1,287-1,500 mg root.
Cystorelief Cystitis Uva-ursi & Echinacea oral dropsa Tincture Echinacea purpurea (L.) Moench herb, Uva-ursi herb (Arctostaphylos uva-ursi (l.) Spreng, Herb) 240 mg of tincture from fresh herb (DER 1:12) per 1 mL. 15 drops in a little water 2-5 times daily. 1mL is equivalent to 30 drops. 240-600 mg of tincture from fresh herb.
Potter’s Elixir of Echinacea Plus/Napiers Elixir of Echinacea Complexb Oral solution Echinacea angustifolia (D.C) root, Wild Indigo root, Fumitory herb 0.64 mL liquid extract from root equivalent to 640 mg root per 5 mL (DER 1:1). 5 mL three times a day for no longer than 10 days. 1.92 mL liquid root extract equivalent to 1.92 g root.
Echinacin Juice MADAUS Oral solution Echinacea purpurea (L.) Moench) herb 117 mg of dried pressed juice from fresh flowering herb equivalent to 3.7 - 6.3 g of fresh herb per 5 mL (DER 31.5-53.6:1). 5 mL three times a day for no longer than 10 days. 351 mg dried pressed juice equivalent to 11.1 - 18.9 g fresh herb.
Echinacin Liquidum MADAUSc Oral solution Echinacea purpurea (L.) Moench) herb 1.99 g of pressed juice from fresh flowering herb equivalent to 3.4 - 5 g of fresh herb per 2.5 mL (DER 1.7-2.5:1). 2.5 mL three times a day for no longer than 10 days. 5,970 mg pressed juice equivalent to 10.2-15 g fresh herb.
Echinaforce hot drink cold & flu echinacea concentrate for oral solution Tincture Echinacea purpurea (L.) Moench herb and root 1,140 mg extract (as tincture) from fresh herb (DER 1:12-13) and 60 mg extract (as tincture) from fresh root (DER 1:11-12) per 5 mL. Days 1-3: Take 5 ml diluted in hot water five times daily. Days 4-10: Take 5 ml diluted in hot water three times daily. 3,420 - 5,700 mg herb extract (tincture) and 180-300 mg root extract (tincture).
Echinaforce Sore Throat Sprayd Oromucosal spray Echinacea purpurea (L.) Moench herb and root, Sage leaves, (Salvia officinalis L. folium) 863.3 mg tincture from fresh herb (DER 1:12) and 45.5 mg tincture from fresh root (DER 1:11) per 1 mL. 1 spray (0.22 mL) six to ten times a day for no more than 7 days. 1,147 - 1,910 mg herb tincture and 60 - 100 mg root tincture.
Duchy Herbals Echina-Relief Tincturee Tincture Echinacea purpurea (L.) Moench root 1mL of tincture from dried root (1:3) (equivalent to 33 mg dried root) per 1 mL tincture. 2.5 ml of tincture, in water, two or three times daily for no longer than 10 days. 5-7.5 mL tincture equivalent to 165 - 248 mg dried root.

a. 1 mL contains 426 mg ethanol equivalent to 10.8 mL beer or 4.5 mL wine (43% v/v ethanol content).

b. 5 mL contains 760 mg ethanol equivalent to 19 mL beer or 7.9 mL wine (19 % v/v ethanol content).

c. 1 mL contains 179 mg ethanol equivalent to 4 mL beer or 1.6 mL wine (18% v/v ethanol content).

d. 1 mL contains 370 mg ethanol equivalent to 8.4 mL beer or 3.4 mL wine (38-42% v/v ethanol content).

e. 2.5 mL contains 900 mg ethanol equivalent to 23 mL beer or 10 mL wine (38-45% v/v ethanol content).

Table 14. Summary of doses and preparations of THR products in the UK and EMA monographs

Echinacea species Daily dose THR products UK EMA monographs daily doses
Echinacea purpurea Pressed juice from herb (DER 1.7-2.5:1): 5,970 mg (equivalent to 10.2-15 g fresh herb) Dried pressed juice from herb (DER 20-28:1): 176-352 mg (equivalent to 3.5 - 9.8 g fresh herb) Dry root extract (DER 6-7:1): 143 - 429 mg (equivalent to 858 - 3,000 mg root) Powdered root: 250 -1500 mg Pressed juice from herb (DER 1.5-2.5:1): 6 - 9 g (equivalent to 9 - 22.5 g fresh herb) Dried pressed juice: Corresponding to the expressed juice above (EMA monograph, 2014) Dry root extract (DER 5.5-7.5:1): 360 mg (equivalent to 1,980 - 2,700 mg root) (EMA monograph, 2017)
Echinacea angustifolia Dry root extract (DER 4.5:1): 660 mg equivalent to 2,970 mg root. Liquid root extract (DER 1:1): 1.92 mL (equivalent to 1,920 mg root) Powdered root: 500-1,500 mg Liquid root extract (DER 1:1): 0.75 - 3 mL (equivalent to 750 -3,000 mg root) Tincture (DER 5:1): 3-6 mL (equivalent to 1,500 - 3,000 mg root) (EMA monograph 2012)
Echinacea pallida Dry root extract (DER 4-9:1): 9.2 mg E. pallida and 9.2 mg E. purpurea (equivalent to 36.8-82.8 mg root) Powdered root : 400 mg E. pallida and 400 mg E. purpurea Dry root extract (DER 4-8:1): 90-96 mg (equivalent to 360 - 786 mg root) (EMA monograph 2018)